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 Abstract 
Protein-protein interactions (PPIs) play an essential role in regulating cellular processes. 
Although long regarded as undruggable, PPIs have recently become attractive targets for drug 
design. One family of proteins that functions entirely through PPIs is the LIM domain-only 
(LMO) family. LMO protein 4 (LMO4) is a transcriptional co-regulatory protein that 
contributes to varied developmental processes as well as the pathogenesis of breast cancer, 
although the mechanism or mechanisms involved are only partially known. The development 
of inhibitors of LMO4 could form useful research tools for understanding these mechanisms 
of action and might also form the basis of new breast cancer therapies. Peptide binders can 
form an excellent starting point for designing inhibitors of PPIs. Previously, the Matthews 
Laboratory has worked with peptide inhibitors of LMO4 that were based on natural binding 
partners of LMO4. Although it was possible to generate peptides that bound LMO4 with 
higher affinity, these β-strand peptides lacked specificity for LMO4.  
The hypotheses underlying this thesis is that α-helical peptides can be more specific than β-
strand peptides, and that it should be possible to generate α-helical peptide binders of LMO4, 
using natural α-helices as templates. The aims for this thesis were to further develop two 
methods to identify novel α-helical peptides that bind to LMO4: a split EGFP system providing 
a high through-put method for the initial screening of a library of α-helical peptides; and, a 
Yeast Two Hybrid Competition Assay (Y2HCA) as an orthogonal method to validate hits and 
provide an assessment of the relative binding affinities of the α-helical peptides. For the 
Y2HCA work, several new constructs were investigated to span a range of different binding 
affinities. A new construct was added to a series of tethered LMO4-CtIPLID constructs to 
provide some relative assessment of the affinities of weakly binding peptides. Two other 
constructs were not suitable for this purpose but do appear to stabilise LMO4 to increase 
sensitivity for detecting LMO4-peptide interactions by this method.  
The split EGFP complementation system previously designed during my Honours year was 
further developed with positive and negative controls. A construct to screen a library of α-
helical peptides for affinity to LMO4LIM1 was also developed. Naturally occurring α-helices 
were considered for their suitability as templates, and three - BAD, HIV-1 GP41 and PUMA - 
were tested in the split EGFP system. Attempts were made to introduce an mCherry 
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expression control to the split EGFP system. Chemical transformation into BL-21(DE3) was 
optimised to allow efficient expression of the library. To facilitate library screening plasmid 
DNA extraction protocols from BL-21 (DE3) cells were also developed. This thesis provides 
mechanisms to identify α-helical peptides that bind to LMO4 and provides the ground work 
to make a high-throughput library screen possible.  
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Abbreviations 
3-AT 3-amino-1,2,4-triazole MQW MilliQ® water 
CtIP C-terminal Binding Protein-
interacting protein 
OD600nm Optical density at 600 nm 
DMSO Dimethyl sulfoxide OD700nm Optical density at 700 nm 
E. coli Escherichia coli PBS Phophate-buffered Saline 
EDTA Ethylenediamine tetra-acetic 
acid 
PAGE Polyacrylamide gel 
electrophoresis 
EGFP Enhanced Green Fluorescent 
Protein 
PCR Polymerase chain reaction 
FACS Fluorescence Activated Cell 
Sorting 
PEG Polyethylene glycol 
GFP Green Fluorescent Protein  PMSF Phenylmethanesulfonyl fluoride  
HRV-3C Human Rhinovirus 3C PPI Protein-protein interaction 
IPTG Isopropyl β-D- 
thiogalactopyranoside 
SD Synthetic dextrose 
LB Luria-Bertani broth SDS Sodium dodecyl sulphate 
LDB1 LIM domain binding protein 1 TAE Tris/acetate/EDTA 
LID LIM interaction domain Tris Tris(2- 
carboxymethyl)aminomethane 
LIM Lin1 Isl1 Mec3   
LIM-HD LIM-homeodomain X-α-gal 5-bromo-4-chloro-3 
indolyl-α-D- 
galactopyranoside 
LMO LIM only protein YPD Yeast peptone dextrose 
LMO4 LIM only protein 4 Y2HCA Yeast 2 Hybrid Competition 
Assay  
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Chapter 1: Introduction  
Protein-protein interactions (PPIs) play an essential role in regulating and controlling cellular 
processes. PPIs involve direct contact between two or more proteins, where the binding can 
be mediated by short sequences or larger folded domains. PPIs allow the formation of protein 
complexes that have important functional roles in biology. Manipulating PPIs with inhibitors 
and/or agonists can be a possible method for treatment of disease, which means that some 
PPIs have become targets for drug design. Inhibitors and agonists can also be used as tools to 
better understand the role of certain PPIs within cells. One protein that is thought to function 
entirely through PPIs is LIM-only protein 4 (LMO4), which is reported to bind a variety of 
protein partners and regulate numerous cellular processes (1, 2). 
1.1  LMO4 
1.1.1 Function  
Members of the LIM domain-only (LMO) family of proteins are generally thought of as 
transcriptional co-regulators that mediate their functions solely via PPIs (3-5). There are four 
LMO proteins in mammals, LMO1–4, which play crucial roles in cell fate determination, cell 
growth and differentiation (1).  
LMO4 is a negative regulator of differentiation (6) and a positive regulator of cell proliferation 
(7-9) in the mammary epithelium. It plays an essential role in organ development such as 
neural tube closure and inner ear development, especially in the cochlea (10-12). LMO4 acts 
at different stages of the cell cycle, likely by affecting the transcriptional programs or by 
interacting with proteins that control the cell cycle (1). There are many mechanisms through 
which LMO4 may produce transcriptional effects. LMO4 may repress transcription through 
the recruitment of co-repressor proteins such as CtIP/RBBP8 (C-terminal Binding Protein-
interacting protein/retinoblastoma binding protein 8)(13) and MTA1 (metastasis-associated 
protein 1) (14). In contrast, it may activate transcription by recruiting GATA factors (15) and/or 
preventing HDAC2 from binding to chromatin (9).  
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1.1.1 Structure 
LMO4 essentially contains only two tandem LIM domains (LIM1 and LIM2; Figure 1.1A). Each 
domain is approximately 60 residues in length and contains two sequential zinc coordinating 
modules (Figure 1.1A). Each module comprises two β-hairpins followed by an α-helix of up to 
eight residues (4). In LMO proteins, the two LIM domains are separated by a short two-residue 
linker (4).  
All well-characterized LMO4-binding proteins bind to their target via a LIM interaction domain 
(LID). These binding proteins are LIM domain-binding protein-1 (LDB1), CtIP and Deformed 
epidermal autoregulatory factor-1 (Deaf-1). However, there are many additional potential 
binding partners that appear to confer roles to LMO4 in a variety of regulatory pathways. 
These partners include the basic loop-helix-loop proteins, nescient helix-loop-helix 1 (16) and 
neurogenin-2 (17), estrogen receptor α (14), neogenin (18), TGF-β family protein BMP7, 
HDAC1 and 2 and MTA1 (2, 9). 
It is difficult to express and purify isolated recombinant LMO4, as it is highly insoluble and 
prone to aggregation. To overcome this problem, the LIM domains of LMO4 can be tethered 
via a flexible linker sequence to the LID of a binding partner (19, 20) (Figure 1.1B). Using this 
strategy, the structures of LMO4 in complex with each of LDB1, CtIP or Deaf-1 have been 
determined (Figure 1.1B-D) and the interactions well characterized (2, 21, 22). The tethering 
strategy works well for these LMO4-LID complexes because the N- and C-termini of LMO4 lie 
close to the C- and N- termini, respectively, of the LID within the complex (Figure 1.1C and D). 
This arrangement and the validity of the tethering approach were confirmed through several 
methods. For example, a protease cleavage site was placed in the linker of a tethered LMO4-
LDB1 complex. 15N-HSQC spectra of the intact and cut complexes were identical, apart from 
peaks arising from residues at the cut site, indicating that the topology of the complex was 
not dependent on the intact linker (20).  
LDB1, CtIP, and Deaf-1 each target the same face on the LIM domains of LMO4 and therefore 
bind in a mutually exclusive manner (22) (Figure 1.1E and F). Each partner contains a ~30-
residue LID that share little sequence identity; however, they have higher similarity in terms 
of amino acid composition. The LIDs contain two linear binding motifs that form an extended 
interface across both LIM domains, forming a series of β-strands that interact with β-hairpins 
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in the LIM domains (e.g. Figure 1.1D) (2, 19, 22-24). The linear binding motifs are specific for 
LIM1 or LIM2 (Figure 1.1C and D) (19). The formation of β-strands at the interfaces means 
that backbone-backbone hydrogen bonds and extensive hydrophobic contacts are a feature 
of binding at both LIM domains. However, mutagenic studies have demonstrated that LIM1-
partner interactions tend to be focused on a single binding hotspot, with a bulky hydrophobic 
sidechain residue (or two residues in the case of CtIP) buried in a hydrophobic binding pocket 
between the two Zn-coordinating modules in LMO4-LIM1 (22, 24). LIM2-partner interactions 
appear to have a more extended binding interface, featuring surface interactions of 
hydrophobic sidechains. These differences, along with a small number of electrostatic 
interactions, are thought to direct the orientation and specificity of binding (19, 21, 23).  
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Figure 1.1: Structure of LMO4 and LMO4-LID complexes. (A) Schematic of LMO4 showing LIM 
domains. (B) Tethered LMO4 and LDB1 construct (C) tethered LMO4 and LDB1 with LMO4 
binding to LDB1. (D) Structure of a tethered LMO4-LDB1 complex; LMO4 Zn-binding modules 
are alternating cyan and magenta with LDB1 in yellow. The numbering shows elements of the 
secondary structure of LDB1 (as determined by the 1D).  Figure taken from Deane et al (19). 
(E) Structure of LDB1 and CtIP in complex with LIM1 of LMO4, LDB1 is yellow, CtIP is red, LIM1 
in complex with LDB1 is blue, LIM1 in complex with CtIP is light blue. (F) Structure of LDB1 and 
Deaf-1 in complex with LIM2 of LMO4, LDB1 is yellow, Deaf-1 is green, LIM2 in complex with 
LDB1LID is blue, LIM2 in complex with Deaf-1LID is light blue. Images were generated from 
PyMOL using the coordinates of PDB codes 2L4Z (LMO4-CtIP)(22), 2MBV (LMO4-Deaf-1)(2) 
and 1RUT (LMO4-LDB1)(19), respectively.  
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1.1.2 LMO4 in breast cancer  
LMO4 is expressed at high levels during pregnancy, where it plays key roles in remodelling of 
mammary tissue (6, 9, 25). It is also overexpressed in over half of breast cancers, where levels 
of expression positively correlate with tumour progression and poor prognosis (1, 6-8, 25-27). 
The exact mechanisms of LMO4 function in tumourigenesis are unknown, but changes to the 
regulation of proliferation, differentiation and apoptosis are common to all types of LMO4 
positive breast cancers (7, 13, 28). Trastuzumab is an effective antibody drug for HER2 positive 
breast cancer, but resistance to this drug has been recently been associated with the 
overexpression of LMO4 (27). CtIP and BRCA1 are tumour suppressor proteins (29-32). One 
hypothesis is that the overexpression of LMO4 in cancer tissue may sequester CtIP to prevent 
CtIP from fulfilling its roles in DNA repair (where it interacts with BRCA1) and thereby 
contribute to a decrease in tumour suppression activity (13, 22). Another possible role of 
LMO4 in tumorigenesis is as a co-activator of transforming growth factor β (TGF-β) signalling 
(33). Thus, overexpression of LMO4 could increase the proliferation of epithelial cells by 
amplifying TGF-β signalling (33).  
1.1.3 Inhibition of LMO4 
Forced overexpression of LMO4 in mouse and human mammary epithelium contributes to 
mammary tumorigenesis by promoting cell proliferation and motility (7, 27). Indeed, the 
levels of LMO4 overexpression correlate with proliferation rates (8). In contrast, down-
regulation of LMO4 using RNAi was shown to significantly reduce the proliferation, migration 
and invasion of both human and mouse breast cancer cell lines (8, 25, 33). 
Given these properties, the inhibition of LMO4 is a potential strategy for both the 
investigation of the mechanism of action of LMO4 and for the development of diagnostics 
and therapeutics for breast cancer. The inhibition of specific LMO4-associated PPIs with small 
molecules or peptides, rather than broad based knockdown strategies (such as with RNAi) has 
the potential to allow a subset of regulatory pathways to be blocked, which may provide an 
advantage for research (to probe specific pathways) or therapy (to minimise side-effects).  
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1.1.4 Inhibition of LMO4’s PPIs using peptides 
Previously the Matthews laboratory focused on developing β-strand peptide inhibitors of 
LMO4, based on the natural binding partners of LMO4. Both specificity and affinity are vital 
components of inhibitor design. However, all LMO and LIM-HD family proteins contain LIM 
domains that are recognised by LDB1. Ideally an inhibitor should specifically target LMO4 and 
not other family members, to minimize off-target affects that might lead to toxicity, while 
maintaining reasonable levels of binding affinity that are required for efficacy.  
Attempts were made to increase the binding affinity and specificity of LDB1 sequences using 
random mutagenesis around binding hotspots, coupled with selection by phage display (J. 
Duncan, R. van den Hoven, unpublished). In other work, collaborators at the University of 
North Carolina used a structure-based in silico method to design variants of LDB1 that were 
optimised for binding to LMO4, which were tested in yeast two hybrid (Y2H) assays in the 
laboratory (P. Stokes & M. Petitmangin, unpublished). Lastly, chimeric peptides generated by 
fusing the LIM1-binding LID region of CtIP and the LIM2-binding LID region of Deaf-1 were 
tested for binding (P. Stokes, unpublished). Overall, those peptides with improved binding 
properties tended to display increased binding affinity but decreased specificity, or decreased 
affinity with increased specificity. 
1.1.5  Converting from β-strand to α-helical inhibitors 
It is likely the lack of specificity is linked to the properties of β-strands. In particular, most of 
the stabilising features of the LMO4-peptide interfaces are intrinsically non-specific, formed 
by backbone-backbone hydrogen bonds and hydrophobic sidechain interactions. In contrast, 
α-helical peptides generally interact with partners using sidechains. Moreover, α-helical 
peptides have been engineered to have increased specificity and affinity in other systems (34, 
35)  
The hypothesis that underlies this thesis is that helical, rather than β-strand, peptide 
inhibitors of LMO4 could provide increased specificity. There are several factors that point to 
the feasibility of this hypothesis. Interaction surfaces on proteins tend to be plastic, able to 
adapt to bind structurally different targets. LIM domains, including those of LMO4 are 
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intrinsically flexible making them able to accommodate different binding partners (2, 21), and 
are made up of small elements of secondary structure joined by loops. These features enable 
LMO4 to adopt altered conformations when binding to different partners (19). For example, 
LMO4 adopts a slightly different conformation when bound to CtIP compared with LDB1 
(Figure 1.1E), accommodating two sidechains in the cleft between the two Zn-modules in 
LMO4LIM1 in the case of CtIP binding, rather than one for LDB1 (22). Thus it is reasonable that 
the specific sidechain interactions of an α-helix, while different to that of the natural β-strand 
LID, are likely to be accomodated by LMO4. The binding face on LMO4 that β-strands interact 
with is very broad and thus would need little remodelling to accommodate an α-helix rather 
than a β-strand.  
1.2 Initial Screening system for library of α helical peptides: EGFP 
Complementation  
 
The general strategy chosen for identification of helical peptide binders was to develop a GFP-
based complementation system to screen a library of potential candidates and identify those 
that bind to LMO4. The levels of green fluorescence produced by a reconstituted split GFP will 
be used to identify if binding has occurred and to provide a measure of the affinity of the 
interaction. 
1.2.1 GFP 
Green Fluorescent Protein (GFP) was originally discovered in Aequorea jellyfish (36). The 11-
stranded β-barrel structure of GFP surrounds an α-helix that forms an autocatalytic 
fluorophore (Figure 1.4). Residues S65, Y66 and G67 mature through a series of cyclisation, 
dehydration, and oxidation reactions to become a functional fluorophore only when the 
protein is properly folded (37-39).  
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Figure 1.4: Structure of GFP. β-Barrel structure in green with fluorophore in yellow. Image was 
generated from PyMOL using PDB 2YOG (40).  
 
GFP has been engineered and optimised for a variety of assays. Three common mutations 
(F99S, M153T, and V163A - the ‘cycle 3’ mutations) enhance protein folding, thereby 
increasing whole cell fluorescence during expression without affecting levels of transcription 
and translation in bacteria (41, 42). Two other mutations, S65T and F64L, were discovered to 
make EGFP (Enhanced GFP) (43). The excitation wavelength of EGFP was increased from 395 
nm to 488 nm with a concomitant 35-fold increase in fluorescence intensity compared to wild 
type GFP (43). EGFP also shows enhanced folding and solubility (43). Both sets of mutations 
are combined in ‘folding reporter’ GFP, which has intense whole cell fluorescence due to 
increased native-like folding, solubility, and improved spectral characteristics (42, 44, 45). This 
folding reporter GFP is often used in in vivo assays. 
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1.2.2 Split EGFP Systems  
EGFP has been adapted for use in split EGFP systems, which are used to report PPIs (46). The 
split EGFP systems are a type of protein-fragment complementation assay (PCA) (47). In this 
type of assay two proteins of interest are fused to two fragments of a reporter protein, where 
each of the isolated fragments has no activity (46-49). Interactions between the proteins of 
interest bring the fragments of the reporter gene together, allowing the fragments to 
associate and fold, thus reconstituting the activity of the reporter (Figure 1.5) (46, 47). PCAs 
can utilize many different proteins as reporter proteins (47). Those that use fluorescent 
reporter proteins such as GFP are referred to as bimolecular fluorescence complementation 
assays (BiFCs) (49). In this study, EGFP split in the loops between β-sheets 7 and 8 was utilized 
as a reporter (50). 
 
 
Figure 1.5: Split EGFP System. If the proteins of interest X and Y come together the EGFP 
molecule assembles and fluorescence occurs. Without the interaction the fragments of EGFP 
remain separate and no fluorescence occurs. Figure supplied by Jacqui Matthews.  
 
1.2.3 Split EGFP system to find α-helical peptide inhibitors for LMO4 
Tethered LMO4-LDB1 complexes have previously been adapted for use in a split GFP system 
in the Matthews laboratory. A prototype system using GFP was tested many years ago (M. 
Swanton, unpublished) but not further developed, and a research student developed a BiFC 
assay for use in yeast cells (51). As part of my Honours research project I designed a split EGFP 
system for use in identifying potential α-helical peptides that bind LMO4 (Figure 1.6). EGFP is 
X:Y 
Y X 
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split as above with one segment tethered to LMO4 and the other to an α-helical peptide. If 
the α-helix binds to LMO4 then the two parts of EGFP will be brought together and auto-
fluoresce. Due to the solubility problems associated with recombinant LMO4, this protein and 
the α-helical peptide need to be tethered (Section 1.1.1). The aim was to create a library of 
α-helical peptides in the split EGFP system (Figure 1.6) and overexpress these constructs in E. 
coli cells. The cells would then be screened by fluorescence activated cell sorting (FACS). This 
high throughput method depends on the fluorescence properties of cells (or markers of 
cellular proteins) and sorting of cells to isolate those with high levels of EGFP fluorescence, 
thereby selecting peptides with increased affinity for LMO4.  
Figure 1.6: Schematic showing general design of the split EGFP system. Star = fluorescence 
(A) an α-helical peptide that binds to LMO4 bringing the two fragments of EGFP together to 
produce fluorescence (B) non-binding peptides should not fluoresce. (C) In the positive 
control LMO4 is tethered to LDB1 and binding between the two molecules brings the two 
fragments of EGFP together to produce fluorescence. (D) In the negative control LMO4 is 
tethered to a random peptide and should not bind or produce fluorescence.  
LDB1 
Random 
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1.2.4  Previously created constructs for split EGFP screening 
As part of my Honours research project, tight binding positive controls that produce 
fluorescence (Positive 36 and 45) and non-binding negative controls that do not fluoresce 
(Negative 36 and 45) were created (Figure 1.7). The positive controls (Figure 1.7B and D) 
expressed high levels of fluorescence, and the negative controls (Figure 1.7C and E) showed 
very low levels of fluorescence. These properties were determined by the analysis of the 
soluble fraction by bulk fluorimetry (see Section 3.1) of BL-21 (DE3) E. coli cells expressing the 
constructs.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7: Split EGFP and split EGFP controls. (A) Empty split EGFP. For B-E the N-terminal 
fragment (EGFP-A) is tethered to LMO4, and the EGFP C terminal fragment (EGFP-B) is 
tethered to (A) a 36-residue fragment of LDB1 (residues 295-330) and is termed Positive 36 
(B) a 36-residue Random peptide #1 and is termed Negative 36 (C) a 45-residue fragment of 
LDB1 (residues 295-339) and is termed Positive 45 (D) a Random peptide #1 45 residues (the 
first 36 residues are the same as Negative 36 with nine additional random residues). 
 
Figure 1.7 is the schematic for the key spit EGFP constructs used in this research. For split 
EGFP alone (Figure 1.7A) there is a 6-residue flexible linker between the fragments of EGFP. 
Split EGFP 
E 
B 
C 
D 
A 
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In the remaining constructs (Figure 1.7 B-E) a 3-residue linker separates each of EGFP-A and 
LMO4, and LDB1/Random #1 and EGFP-B, whereas an 18-residue flexible linker that contains 
an HRV-3C protease site separates LMO4 and LDB1/Random #1. This linker has been used 
with a good level of success in several related projects involving LIM-LID constructs (see 
section 1.1.1 for more details). The HRV-3C protease site is not required for the research 
described in this thesis, but it may be useful future.  
 
1.2.5  mCherry 
The original red fluorescent protein was initially discovered in the reef coral Discosoma (52). 
This protein was then substantially engineered to become dsRed and eventually mCherry (53-
55). mCherry (Figure 1.8) is a red fluorescent protein that matures quickly, is photostable and 
monomeric; it has been widely used in biochemistry and cell biology as a fluorescent tag (55). 
mCherry is often used in combination with EGFP (56) because their excitation and emission 
spectra (Figure 1.9) are very different allowing both to be measured without interference 
from the other.  
1.3 α-helical libraries 
 
 
 
 
 
 
 
Figure 1.8: Structure of mCherry. mCherry shares a core β-barrel structure (red) with GFP, 
but folding and autofluoresence results in a variant fluorophore (yellow) that has different 
fluorescent properties. Figure taken from (57).  
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Figure 1.9: Excitation and emission spectra for EGFP and mCherry. The dotted lines for EGFP 
(blue) and mCherry (orange) show the excitation spectra and the shaded areas report the 
emission spectra. This graph was created in ThermoFisher Scientific Fluorescence Spectra 
Viewer. 
1.3 α-helix in the split EGFP context 
Isolated α-helical peptides are often intrinsically disordered and form helical structure only 
upon binding. Folding upon binding was previously shown to be enhanced by tethering α-
helical peptide sequences to another protein or subdomain (58-60). This tethering approach 
is incorporated into the construct design for our split EGFP reporter (Figure 1.7). 
Most studies that have generated α-helical libraries have been based on a naturally occurring 
helical sequence that has intrinsic affinity for a target (or targets)(61-63). There is no known 
α-helix that naturally binds to LMO4 that can be used as a template, but it was decided to 
select existing α-helices from other sources for the library design. The criteria for selection 
were that the α-helices must be well characterised, and have been used previously as a 
template in a peptide library and/or been successfully modulated. Peptides that were 
successfully used in other systems were considered more likely to be successful in similar 
experiments than untested template sequences.  
1.3.1 BCL-2 family proteins 
The B-cell lymphoma (BCL-2) family of proteins contains numerous well-characterised and 
studied α-helices. In particular the BH3 domains within these proteins are α-helices that 
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mediate interactions between partners. BCL-2 and its homologues (Figure 1.10) regulate 
apoptosis through protein-protein interactions. This family includes both pro-apoptotic and 
pro-survival proteins (Figure 1.10) and governs mitochondrial outer membrane 
permeabilisation. Interactions between these proteins determine whether cells undergo 
apoptosis (through mitochondrial permeablisation) or continue to survive.  
 
Figure 1.10: BCL-2 family of proteins. (A) BCL-2 family of proteins and protein domains. (B) 
BH3 α-helix mediated interactions between BCL-2 family members. Taken from (64).  
 
BCL-2 and its homologues show sequence homology in four helical domains BH1–4 (65) that 
form a helix bundle. The multidomain BCL-2 proteins interact with different subsets of BH3-
containing proteins, with varying affinity, to achieve pro-apoptotic or pro-survival outcomes 
(66, 67). In BH3-only proteins, the BH3 domain is disordered but forms an amphipathic α-helix 
upon binding to a common groove on multidomain BCL-2 proteins (64, 68) (Figure 1.11). BH3-
only proteins BIM and PUMA bind with high affinity to all pro-survival proteins, causing 
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inhibition to promote apoptosis (Figure 1.10B). The other BH3-only proteins (BIK, BAD, BMF 
and HRK) interact only with BCL-2 and BCL-XL with low binding affinities to weakly promote 
apoptosis (69).  
 
Figure 1.11: BH3 domain of Puma interacting with the major hydrophobic grove of BCL-2 
protein (MCL-1). BH3 α-helix of Puma (orange) interacting with Mcl-1 (blue). Image 
generated in PyMOL using PDB 2ROC (70).  
 
1.3.1.1 Developing novel α-helices based on the BH3 domain 
The BH3 domain is an amphipathic α-helix containing the sequence motif A-X-X-X-A-X-X-A-B-
C-X-A; where A is a hydrophobic residue, B is a smaller residue (often glycine) and C is 
aspartate or glutamate (71). When bound, the A and/or the B residues in the motif form the 
hydrophobic side of the helix that contacts partner proteins (71, 72). Many small molecule 
BH3 mimics and synthetic BH3-derived peptides have been generated that inhibit PPIs in the 
BCL-2 system (73). For example, BH3-based α-helical peptides were generated to bind with 
increased selectivity to various BCL-2 proteins (34). Both positive steps to improve affinity and 
negative steps to improve specificity were included in the design process. These helices 
inhibited native PPIs in fluorescence polarization and fluorescence-based Y2H assays (34, 72). 
Using this approach, the investigators were able to create a novel α-helical peptide inhibitor 
for BCL-XL(34).  
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1.3.2 Other α-helices  
Another naturally occurring α-helix that has been used in peptide libraries and/or has been 
successfully modulated to improve affinity is Son of Sevenless (SOS), which interacts with Ras 
(small GTPase) via an α-helix called αH (74). A rational structure-based iterative design 
process was deployed to improve the affinity of αH for Ras. The resultant peptide was used 
as the basis for design of a small molecule that mimicked the peptide structure (74).  
α-helical peptides that bind to VEGF receptors (VEGFR) have been taken from the N-terminus 
of vascular endothelial growth factor (VEGF) and Vammin (a form of VEGF found in snake 
venom)(35). In silico approaches were used to develop peptide libraries designed to have 
improved specificity and affinity to VEGFRs. The peptide library was created by solid-phase 
synthesis and screened for binding to VEGFRs. A peptide was identified that bound to VEGFR-
1 with greater affinity than VEGF (35). A similar in silico and solid phase synthesis selection 
approach was used to examine VEGF and receptor Flt-1 as well as p53 and MDM2 (75).  
Other helical peptide candidates are an α-helix from the p53 tumour suppressor that binds to 
E3 ubiquitin-protein ligase (MDM2) (76). An α-helix from Avian Pancreatic Polypeptide that 
binds to a small DNA protein PPBR4, where helices of increased binding affinity were 
generated and selected using phage display (59). Finally, an α-helix from HIV-1 envelope 
protein GP41. Using rational design, the C-terminal α-helical region of GP41 was used in the 
development of the drug enfuvirtide, which binds to the different region of GP41 and blocks 
HIV-1 entry into cells (63, 77).  
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1.3.3 Using an α-helix as a template  
One of the benefits of using α-helices whose structures have been solved is the ability to know 
which residues form the natural binding interface (Figure 1.12), and solely manipulate these 
residues to create a library of variants that could bind to LMO4. This is typical of the design of 
α-helical libraries (74-76). The approach maintains the propensity to form an α-helix whilst 
modulating binding properties and minimizes the size of the library as only a subset of 
residues need to be randomised.  
Figure 1.12: The BH3 α-helices showing interacting residues. (A) BH3 α-helix of BIM 
interacting with BCL-2. The interacting residues are labelled in terms of their position in the 
peptide sequence. (B) Amino acid sequence of BH3 domains in BCL-2 family proteins. Of the 
30 residues shown, those assigned numbers and letters correspond to the main part of the 
helix are labelled in panel A. Figure taken from (61). 
 
1.3.4 α-helical mimetics  
 α-Helical mimetics are compounds that mimic the structural configuration of α-helices but 
utilise various non-natural chemistries to stabilise the α-helix (78). Such mimetics may be 
highly helical and can be very resistant to proteolysis in vivo. At this stage of the project such 
mimetics are not useful because they cannot be readily incorporated into the EGFP reporter 
constructs. However, α helical mimetics are showing promise as good drug candidates, and if 
suitable α-helical peptide inhibitors of LMO4 can be identified, conversion into mimetics 
could be a viable step towards the development of drugs.  
 
A B 
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1.4 Yeast two hybrid competition assay (Y2HCA) 
1.4.1 Yeast two hybrid (Y2H) assay 
Yeast two-hybrid assays are used to determine if two proteins, termed the bait and the prey, 
will interact (79). Y2H assays have been used previously to assess possible binding partners 
and potential LID-based inhibitors for LMO4 (2, 19, 22, 23). For example, the prey LID protein 
can be fused to the transcriptional activation domain of the transcription factor GAL4, with 
the bait LIM protein fused to the DNA binding domain of GAL4 (Figure 1.13). An interaction 
is detected by activation of reporter genes, which are usually associated with yeast growth 
under nutritional selection conditions and/or the production of colour. Although Y2H assays 
are able give a qualitative assessment of binding, it can be difficult to assess the relative 
affinity of an interaction, and the assay cannot distinguish binding affinities that lie above or 
below the threshold of detection.  
 
 
Figure 1.13: Schematic of the Y2H system. AD: Activation domain, DNA-BD: DNA binding 
domain. Figure from Clontech Matchmaker® Gold Yeast Two Hybrid System User 
Manual.  
1.4.2 Yeast two hybrid competition assay  
Yeast two hybrid competition assays are an extension of traditional Y2H assays that provide 
a means to better discern relative binding affinities for similar binding partners. In this 
system, instead of LMO4 alone, a tethered LMO4–LID construct is used as bait. The LID that 
is being assessed must ‘compete off’ the tethered LID peptide before it can bind LMO4 (M) 
(Figure 1.14). 
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This approach was used previously to investigate the relative strength of an intramolecular 
interaction in Isl1 (80). Isl1LID tethered to ISL1LIM1+2 was fused to the Gal4 activation domain, 
whereas LDB1LID peptides were fused to the Gal4 binding domain (80). The Isl1LID and 
Isl1LIM1+2 interaction was too weak to be detected in standard Y2H assays but could inhibit 
LDB1 binding in the context of the tethered LIM-LID complex (80).  
 
 
 
 
Figure 1.14: Schematic of the yeast two hybrid competition assay. In order for the LID to 
bind to LMO4 it must first compete off the tethered peptide (M). Then the two parts of the 
GAL4 are brought together to activate transcription of the reporter genes allowing the yeast 
to grow on nutritionally selective media, and produce a blue colour in the presence of X-α-
gal.  
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1.4.3 Previous Development of Yeast 2 Hybrid Competition Assay for 
LMO4 binders 
 
Figure 1.15: Tethered LMO4 constructs previously used in the Y2HCA 
  
The relative binding affinities for LMO4 of for test LIDs (Section 1.1.4) were assessed by 
other members of the Matthews laboratory using both Y2H and Y2HCA systems. Most of 
these LIDs bind very well in the standard Y2H assay but can’t be easily ranked in terms of 
binding affinities. In the Y2HCA (initially developed by P. Stokes and M. Petitmangin, 
unpublished data) a range of tethered constructs were utilised in which CtIPLID was the 
weakest binding partner (Figure 1.15). It was the only construct to be effectively competed 
off by LDB1 (positive control). The test LIDs could not compete with tethered CtIP for 
binding to LMO4 so could not be further assessed in the Y2CA in that form. During my 
Honours project research CtIP mutant constructs were designed to bind to LMO4 more 
weakly than CtIP and thus be capable of being competed off by weak LIDs. These 
constructs were cloned and preliminary experiments carried out, and are reported in 
Chapter 3 (Section 3.1) as an introduction to that part of the work carried out for this 
thesis. 
 
 
 
CtIP 
Strength of 
binding to LMO4 
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1.5 Aims of thesis 
The key aims of this thesis were to further develop and refine two methods: a split EGFP 
system providing a high throughput method for initial screening of an α-helical peptide 
library; and Y2HCA, an orthogonal method for validating hits and providing an assessment of 
the relative binding affinities of α-helical peptides in a moderate throughput manner.  
 
Chapter 3 describes efforts to test constructs for Y2HCA that were designed during my 
Honours year, and to incorporate new designs to try and expand the usefulness of the Y2HCA 
for testing weakly binding peptides.  
 
Chapter 4 describes efforts to further develop a split EGFP system with positive and negative 
controls that can detect potential LMO4 α-helical binders. Studies described in this thesis 
build on research that was initiated during my Honours year and focuses on generating 
capacity to detect helical elements that bind to a single LIM domain in LMO4, and introduces 
a new mCherry element for assessing cellular levels of expression.  
 
Chapter 5 describes efforts to design the α-helical library for the split EGFP complementation 
system. It also describes efforts to optimise chemical transformation protocols and plasmid 
DNA extraction from cells to aid in the screening of the library.  
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Chapter 2: Materials and Methods 
2.1 Materials  
2.1.1 Chemicals and Reagents  
Table 2.1 shows all chemicals and reagents used throughout this project. Solutions were 
prepared in MilliQ® water (MQW) (18.2 MΩ.cm Resistivity). 
  
Table 2.1: Chemicals and reagents used in this project  
Chemical/Reagent Supplier 
2-log DNA ladder New England Bio Labs (Beverly, MA) 
2-β-mercaptoethanol Sigma-Aldrich (Castle Hill, NSW) 
3-Amino-1,2,4-triazole (3-AT) Sigma-Aldrich (Castle Hill, NSW) 
5-bromo-4-chloro-3-indolyl-α-D- 
galactopyranoside (X-α-gal) 
Astral Scientific (Caringbah, NSW) 
Adenine (A) Sigma-Aldrich (Castle Hill, NSW) 
Agarose Affymetrix (Santa Clara, CA) 
Ampicillin Sigma-Aldrich (Castle Hill, NSW) 
Bacterial peptone Affymetrix (Santa Clara, CA) 
Bacteriological agar Affymetrix (Santa Clara, CA) 
CaCl2 Ajax Finechem (Taren Point, NSW) 
Chloramphenicol Amresco (Solon, OH) 
Complete protease inhibitor cocktail 
tablets 
Roche Applied Science (Castle Hill, 
NSW) 
Complete supplement mixture (CSM) – 
ade-his-leu-trp 
MP Biomedicals, LLC (Solon, OH) 
Deoxyribonucleotide triphosphates 
(dNTPs) 
Roche Applied Science (Castle Hill, 
NSW) 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich (Castle Hill, NSW) 
Ethanol Chem-Supply (Gillman, SA) 
Ethylenediaminetetraacetic acid (EDTA) Ajax Finechem (Taren Point, NSW) 
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Glucose Univar (Auburn, NSW) 
Glycerol Chem-Supply (Gillman, SA) 
HCl Univar (Auburn, NSW) 
Histidine (H) Sigma-Aldrich (Castle Hill, NSW) 
HydraGreen™ Safe DNA Dye ACTGene Inc. (Piscataway, NJ) 
Isopropyl β-D-thiogalactopyranoside 
(IPTG) 
Progen (Darra, Qld) 
KCl Ajax Finechem (Taren Point, NSW) 
KH2PO4 Chem-Supply (Gillman, SA) 
Lithium acetate (LiAc) Ajax Finechem (Taren Point, NSW) 
Methanol Chem-Supply (Gillman, SA) 
MgCl2 Ajax Finechem (Taren Point, NSW) 
Mg2SO4 Ajax Finechem (Taren Point, NSW) 
Monomeric bovine serum albumin (BSA) New England Bio Labs (Beverly, MA) 
Na2HPO4 Ajax Finechem (Taren Point, NSW) 
NH4Cl Ajax Finechem (Taren Point, NSW) 
NaCl Chem-Supply (Gillman, SA) 
NaOH Chem-Supply (Gillman, SA) 
Paraformaldehyde Sigma-Aldrich (Castle Hill, NSW) 
Phenylmethylsulfonyl fluoride (PMSF) Sigma-Aldrich (Castle Hill, NSW) 
Polyethylene glycol, MW 4000 (PEG) Hampton Research (Aliso Viejo, CA) 
Salmon sperm DNA Sigma-Aldrich (Castle Hill, NSW) 
Tris(hydroxymethyl)aminomethane 
(Tris) 
Chem-Supply (Gillman, SA) 
Tryptone Amyl media (Dandenong, VIC) 
Yeast extract Amyl media (Dandenong, VIC) 
Yeast nitrogen base Difco (Detroit, MI) 
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2.1.2 Enzymes 
All enzymes were used with the buffers provided by the manufacturer according to the 
manufacturer’s instructions.  
 
Table 2.2: Enzymes used in this project  
Enzyme Enzyme Commission 
Number (EC) 
Manufacturer 
BamHI EC 3.1.21.4 New England BioLabs (Beverly, 
MA) 
EcoRI EC 3.1.21.4 New England BioLabs (Beverly, 
MA) 
NdeI EC 3.1.21.4 New England BioLabs (Beverly, 
MA) 
HindIII EC 3.1.21.4 New England BioLabs (Beverly, 
MA) 
Phusion Hot Start DNA 
polymerase 
EC 2.7.7.7 Jason Low (University  of Sydney, 
Sydney) 
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2.1.3 Media 
A full list of media used in this project can be found in Table 2.3. All media were prepared in 
MilliQ® water. For solid media, agarose was added to a concentration of 1.5% w/v. All media 
were sterilised by autoclaving before use, with the exception of glucose which was filter-
sterilised and added to autoclaved media. 
 
Table 2.3 Media 
Media Components 
Luria-Bertani broth (LB) 1% w/v peptone, 0.5% w/v yeast extract, 0.5% w/v NaCl 
Yeast peptone dextrose 
(YPD) 
2% w/v tryptone, 1% w/v yeast extract, 2% w/v glucose, 
0.2% w/v adenine 
Synthetic dextrose (SD) 0.65% w/v yeast nitrogen base, 0.4% w/v glucose, 0.016% w/v 
CSM – ade-his-leu-trp,  
SOB 2% w/v Tryptone, 0.5% w/v Yeast Extract, 10 mM NaCl, 2.5 mM 
KCl, 10 mM MgCl2, 10 mM MgSO4 
SOC 2% w/v Tryptone, 0.5% w/v Yeast Extract, 10 mM NaCl, 2.5 mM 
KCl, 10mM MgCl2, 10 mM MgSO4, 20mM Glucose 
YT 2% w/v Tryptone, 0.5% w/v Yeast Extract, 0.1 M NaCl 
Additional nutrients were added to SD media as required 
2.1.4 Oligonucleotides and plasmids  
Single-stranded oligonucleotides used for cloning were synthesised by IDT (Coralville, 
IA). See Appendix A for a full list of sequences used. 
 
The yeast plasmids used throughout this project were pGAD10 (LEU2, ampR) (BD 
Bioscienes Clontech, CA), and pGBT9 (TRP1, ampRp) (M. Crossley, University of Sydney). 
pGBT9 is a modified version of NpGBT9 (Clontech, Mountain View, CA) in which the MCS 
has been modified such that the BamHI and EcoRI sites have been reversed.  
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Bacterial expression plasmids used for split EGFP system were produced using a 
modified pET-15b vector (Novagen, Darmstadt, DEU) termed pET-15be (T. Ohashi, 
Duke University Medical Centre, NC, USA). The vector contains the sequence for an 
N-terminal His-tag, a thrombin cleavage site (LVPRGS) sequence and a multiple 
cloning site (MCS) spanning 12 amino acids (Figure 2.4).  
 
Figure 2.4: Multiple cloning site of pET15BE. 
 
Bacterial expression plasmids used for split EGFP and mCherry was pETDuet -1 vector 
(Novagen, Darmstadt, DEU).  pETDuet -1 is designed for the coexpression of two 
target genes. The vector contains two multiple cloning sites, each of which is 
preceded by a T7 promoter, lac operator and ribosome binding site.  
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2.1.5 Yeast and Bacterial Strains  
Table 2.5 lists the yeast and bacterial strains used throughout this project, and their 
genotypes. The E. coli strain DH5α was used for propagating plasmid DNA, whereas 
recombinant protein overexpression was conducted in the E. coli strains BL-21(DE3), BL-
21 (DE3) Gold and Rosetta™ 2(DE3) pLysS (hereafter referred to as Rosetta 2). Bacterial 
strains were maintained in sterile LB broth or LB agar.  Saccharomyces cerevisiae yeast 
strains were maintained in sterile liquid YPD or YPD agar. 
Table 2.5 Organism strains  
Organism Strain Genotype  
DH5α cells (Betheseda 
Research Laboratories, 
Gaithersburg, MD, USA) 
supE44, ΔlacU169,[Φ80lacZΔMI5], hsdR17, recA1, 
endA1, gyrA96, thi-1, relA1;  
BL-21 (DE3) (Integrated 
Sciences, Willoughby, NSW) 
F- ompT, hsdSB(rB–, mB–),gal, dcm, (DE3) 
BL-21 (DE3) Gold (Agilent, CA, 
USA)  
F– ompT hsdS(rB– mB–) dcm+ Tetr gal λ(DE3) 
endA Hte 
Rosetta™2 (Merck, Dermstadt, 
Germany) 
F_ ompT, hsdSB(rB
- mB
-), gal, dcm,RARE2 (CamR), 
(DE3) 
AH109 (BD Bioscienes Clontech, 
CA) 
MATa, trp1-901, leu2-3, 112, ura3-52, his3 200, 
gal4Δ, gal80Δ, LYS2::GAL1UAS-GAL1TATA-HIS3, 
GAL2UAS-GAL2TATA-ADE2 URA3::MEL1UAS- 
MEL1TATA-LacZ MEL1 
 
2.2 Cloning of CtIP mutant constructs and split EGFP constructs  
The following inserts were generated by PCR amplification  
 M3-LMO4 
 M668A-LMO4 
 D669A-LMO4 
 V670A-LMO4 
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 LDB1 318 
 LDB1 318 Mutant 
 LDB1 315 
 LDB1 315 Mutant 
 mCherry 
 BAD  
 GP41 
 PUMA 
PCR amplification of all inserts was carried out using Phusion DNA polymerase (1 U) in 20 
mM Tris (pH 8.8), 10 mM KCl, 10 mM (NH4)SO4, 2 mM MgSO4, 1% (v/v) TritonX-100, 1 
mg/mL BSA, 0.1 mM dNTPs, 400 nM primers and 50 ng of template DNA. The PCR cycle 
involved denaturation at 95 °C for one min followed by 30 cycles of denaturation (95 °C 
for 1 min), annealing (55 °C for 1 min) and extension (72 °C for 1 min) and a further extension 
step at 72 °C for 10 min. PCR products were run on a 2% agarose gel in TAE buffer (Tris-
acetate buffer; 40 mM Tris, 40 mM acetic acid, 1 mM EDTA), stained with ethidium bromide 
(167 µl/L) or hydra green(25 µl/L), the bands excised and the DNA purified using a gel-
extraction kit according to the manufacturer’s instructions (Bioline, Alexandria, NSW). 
Overlap extension PCR (81) was used to fuse the fragments and amplify the fused DNA. 
Initially the reaction was prepared as above, without primers but including purified PCR 
products. Five cycles of denaturation (95 °C for 1.5 min), annealing (55 °C for 50 s) and 
extension (72 °C for 1 min), were carried out, plus a final extension step at 72 °C for 10 min. 
An aliquot of this 5-cycle reaction was added to a new PCR reaction, including end-primers, 
followed by a round of conventional 30-cycle PCR to amplify the full-length fragment. 
 
The PCR inserts were cloned into the target vector (pGBT9, pET15be, or pETDuet) using 
Gibson Assembly (82). Fragments were amplified by PCR with primers that add a 30 bp 
overlap with the flanking regions of the destination vector, and the products were run on a 
2% agarose gel, bands excised and purified. A Gibson Assembly reaction was set up combining 
this insert with vector linearized by a restriction digest with BamHI and EcoRI for pGBT9 and 
pET15be or NdeI and XhoI for pETDUET, at a 1:3 and 1:6 vector-to-insert molar ratio. The 
reaction mixture was made up to 5 µL with MQW and 5 µL of Gibson Assembly® Master Mix 
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(T4 DNA ligase, T5 exonuclease, Phusion hot start DNA polymerase and recommended buffer) 
was added. The reaction mixture was incubated at 50 °C for 1 h before being DH5α cells were 
transformed. 
The presence of the correct insert was assessed by restriction digestion with HindIII for 
pGBT9 constructs, HindIII and NdeI for pET15be constructs. BamHI and HindIII for pETDuet 
MCS 1 and HindIII and AvrII for pETDuet MCS 2. All constructs were confirmed by DNA 
sequencing conducted by the Australian Genome Research Facility (Westmead, NSW).  
2.3 Experimental methods for Yeast 
2.3.1 Preparation of competent yeast  
Yeast (AH109) were grown in rich YPD media  at  30 °C overnight, with shaking at 200 
rpm. Cells were then pelleted by centrifugation at room temperature, 5 min, 1000 × 
g. Cell pellets were resuspended in 25 mL sterile MQW and combined, before being 
centrifuged again at 1000 × g for 5 min.  Supernatant was removed, and cells resuspended 
in buffer (10 mM Tris, pH 8.0, 1 mM EDTA, 100 mM LiAc (pH 7.5)) in preparation for 
transformations. 
2.3.2 Transformation of competent yeast  
A 100 μL aliquot of competent yeast was added to plasmid DNA (approximately 200 ng of 
pGBT9 and pGAD10 plasmid) and 0 .1  m g carrier salmon sperm DNA. Sterile PEG/LiAc 
solution (600 μL; 40% w / v  PEG 4000, 100 mM LiAc, 10 mM Tris, 1 mM EDTA, pH 
8.0) was added and the solution vortexed at low speed for 5 s. This mixture was then 
incubated for 30 min at 30 °C, shaking at 200 rpm, following which DMSO (70 μL) was 
added. Cells were then heat shocked at 42 °C for 15 min, with gentle mixing every 5 min. 
Cells were then chilled on ice for 2 min. The mixture was then centrifuged at 12000 
x g for 5 s in a microfuge, and the supernatant removed. The cell pellet was resuspended 
in resuspension buffer (300 µL; 10 mM Tris (pH 8.0), 1 mM EDTA). This mixture was 
inoculated onto selective media (SD-LW, SD media with no leucine or tryptophan 
supplementation), for co- transformations. Plates were incubated for 72 h at 30 °C. 
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2.3.3 Yeast 2 Hybrid Spot Tests  
Transformed yeast were grown overnight with shaking in rich SD media (1 mL, 30 °C, 
200 rpm). Cell cultures were then normalised using the optical density of the solution 
at 600 nm with a 1 cm pathlength (OD600). Two 1-in-10 serial dilutions were prepared 
from the normalised cell suspension, resulting in solutions with OD600s of 0.2, 0.02 
and 0.002. Aliquots of each sample were then spotted onto plates at each selection 
condition, as well as growth control plates made from SD-LW. Selection conditions used 
included, from least stringent to most stringent: 
 SD-LW-H+0.5 mM 3-AT – SD-LW-H supplemented with 0.5 mM 3-AT. 
 SD-LW-H+5 mM 3-AT – SD-LW-H supplemented with 5 mM 3-AT 
 SD-LW-H-A – SD-LW with no histidine and no adenine supplementation.  
Exact components of these media are listed in Appendix D. 
2. 4 Production of split EGFP proteins  
2.4.1  Super Competent BL-21 (DE3) Cells 
BL-21 (DE3) cells were grown in 5 ml of YT media at 37 °C overnight, with shaking at 200 
rpm. Cells were added to 100ml YT media at 37 °C, 200 rpm for 2 h.  Cells were then 
pelleted by centrifugation at 5 min, 3000 × g at 4 °C. Cell pellets were resuspended in 
30 mL sterile TFBI (30 mM KAcetate, 50 mM MnCl2, 100 mM  K C l ,  1 0  m M  C a C l 2 ,  1 5 %  
Glycerol ( p H  5 . 8)) and incubated at 4°C for 1.5 h.  C e l l s  w e r e  c entrifuged again  at  
1000  ×  g  for  15  min, 4 °C .  Supernatant was removed, and cells resuspended in TFBII 
(10 mM NaMOPS (pH 7.0), 75 mM C a C l 2 , 10 mM KCl, 15% Glycerol).   
2.4.2  Bacterial transformations  
2.4.2.1 Method for DH5α and Rosetta 2 transformations 
Plasmid DNA (50–500 ng) was added to KCM buffer (10–50 μL; 0.1 M KCl, 30 mM CaCl2, 
50 mM MgCl2). Resuspended competent E. coli cells were then added (10–50 μL). After 
30 min at 4 °C, this mixture was then heat shocked at 42 °C for 90 s. LB media (200 μL)  
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was then added and the solution incubated for 1 h with shaking (37 °C, 150 rpm), before 
the solution was spread onto LB plates containing appropriate selection conditions. 
 
2.4.2.2 Methods for super competent BL-21 (DE3) cells transformation.  
Table 2.5 Methods for super competent BL-21 (DE3) transformation 
Method No.  Procedure 
1 50-300 ng DNA in 20-50 μl super competent cells, 5-10 min on ice, 42 °C 
heat shock for 90 s, 30 s on ice, 1 h recovery with LB, SOC or SOB media at 
37 °C, 200 rpm. Plated onto LB plates containing Ampicillin (100 μg/mL). 
2 50-300 ng DNA in 20-50 μl super competent cells, 30 min on ice, 42 °C heat 
shock for 60 s, 30 min on ice, 1.5 h recovery with LB, SOC or SOB  media at 
37 °C, 200 rpm. Plated onto LB plates containing Ampicillin (100 μg/mL).  
3 0.005-300 ng DNA in 20-50 μl super competent cells, 30 min on ice, 42 °C 
heat shock for 60 s, 2 min on ice, 1 h recovery with LB, SOC or SOB media 
at 37 °C, 200 rpm. Plated onto LB plates containing Ampicillin (100 μg/mL). 
 
The exact amount of DNA, volume of cells and recovery media are noted in Appendix A.  
Method 1 with 20 μL cells, 200ng DNA and LB recovery media is the method used for all BL-
21(DE3) and BL-21 (DE3) Gold transformations unless explicitly stated. 
2.4.3  Protein Overexpression  
BL-21(DE3) cells were transformed by the spEGFP fusion construct plasmids. Single colonies 
were used to inoculate 5ml of LB broth supplemented with 100 μg/mL ampicillin. The 
inoculum was grown with shaking overnight (37 °C,  200  rpm).  These cultures were used to 
inoculate fresh media (10 ml) at a concentration corresponding to an OD600 of 0.05. The 
culture was grown at 37 °C, with shaking at 150 rpm until an OD600 of 0.6–0.8 was 
reached. At this point, IPTG was added to a concentration of 1 mM to induce protein 
overexpression. Cultures were then allowed to continue growing according to Table 2.6. Cells 
were harvested through centrifugation at 5000 × g for 5 min. 
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Table 2.6: Growth Temperatures and Times  
Temperature (⁰C) Growth time after induction 
25 Overnight (12 h) 
20 Overnight (16 h) 
 
2.5 Fluorescence 
2.5.1  Cell Fixing 
After the protein overexpression protocol cells were fixed using paraformaldehyde. Cells 
were resuspended in PBS (10 ml) (Table 2.7) then centrifuged at 5000 × g for 5 min, 
resuspended in 4% Paraformaldehyde and incubated in the dark at room temperature for 
10 min. Cells were washed in PBS (10 ml) before being finally resuspended in PBS (1 ml).  
Table 2.7 Buffers 
Buffer Components 
Phosphate-buffered saline 
(PBS) 
137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM 
KH2PO4 
4% Paraformaldehyde 4% w/v paraformaldehyde in PBS 
Flow Cytometer Buffer 0.5 mM EDTA in PBS 
 
2.5.2  Plate Fluorimetry 
Fluorescence data were collected using the Tecan infinite m1000 plate reader (Tecan Austria 
GmbH). Whole cells samples were prepared at an OD600 of 0.3 in PBS. Cells were read in a 
Costar® black flat bottom 96 well plate. Plate was read at 4 °C, with cells shaken prior to 
fluorescence read. Data were recorded using excitation wavelengths of 478-90nm and 
emission wavelengths of 504-16 nm for EGFP, or excitation wavelengths of 581-93 nm and 
emission wavelengths of 604-16 nm for mCherry, and 400 v gain setting. The data were 
captured using i-control software.  
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2.5.3  Fluorescence Spectroscopy 
An Olympus BX51 Microscope (Olympus, New York) with a reflected fluorescence system 
was used to image cells by fluorescent microscopy. Cells were resuspended in PBS buffer at 
an OD600 of 0.3. Other components included a Mercury Burner (U-RFL-T), and F- view 
monochrome fluorescence camera with FITC (495 nm/515 nm [#31001])) Chroma filter. 
Micrographs were captured using AnalySIS LS Starter (Olympus Soft Imaging Systems, ver. 
2.8). 
2.5.4  Flow Cytometry 
Flow cytometry data were collected using a BD Accuri C6 plus desktop flow cytometer (BD 
Biosciences, California) and BD Accuri software. Samples of 1 x 106 fixed cells in flow 
cytometer buffer were run through the flow cytometer at room temperature. The filters 
used had an excitation range of 470-90 nm and emission wavelengths of 500-20 nm for 
EGFP, or an excitation range of 570-90 nm and emission wavelengths of 600-20 nm for 
mCherry. Flow Cytometry data were analysed using FlowJo V10 (FlowJo LLC, Oregon).  
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 Chapter 3: Yeast Two Hybrid Competition Assay  
Previously, as part of an Honours research project (G. McClymont, Honours Thesis in 
Biochemistry, The University of Sydney, 2016) Y2HCA experiments with a range of LID-LMO4 
tethered constructs (Section 1.3.2) had been developed to assess the relative binding 
affinities of potential peptide inhibitors of LMO4. In the broader context of this thesis the 
Y2HCA acts as an orthogonal validation tool to confirm that peptides identified by the split 
EGFP complementation assay are LMO4 binders, as well as to provide a qualitative 
assessment of their binding strength. It is expected that the hits from an initial screen will be 
very weak binders, so the Y2HCA needs to be sufficiently sensitive to detect and assess 
differences between weak binders.  
The aim of my Honours project was to expand the range of Y2HCA tethered constructs to 
include weaker LIDs tethered to LMO4 that would create a more sensitive assay capable of 
detecting and assessing the binding of weakly interacting peptides. The weakly binding LIDs 
chosen were based on CtIPLID (itself the naturally occurring LID with the weakest known 
binding affinity for LMO4) with mutations to further weaken the LID-LIM interaction. I 
generated the triple alanine mutations of CtIP, M1 and M2 (Figure 3.1), M1 encompasses the 
mutations M668A, D669A and V670A. M2 encompasses the mutations T671A, V672A and 
I673A. These were two of a series of triple alanine mutants designed to probe the LMO4-
binding interface of CtIPLID (22, 83). Preliminary data suggested the resultant peptides bound 
LMO4 so weakly that they were easily displaced by all LIDs tested. However, the results were 
inconclusive as the experiment was only conducted once and there were issues with the 
controls affecting the validity of that single experiment.  
 
 
 
Figure 3.1: CtIP triple alanine mutant constructs M1 and M2. M1 and M2 are tethered at the 
C-terminus via an 11-residue flexible linker to the N-terminus of LMO4. These constructs are 
both sub-cloned into the plasmid pGBT9.  
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Figure 3.2 Y2HCA for M1-LMO4 and M2-LMO4 against test LIDs. (A) Y2HCA schematic (B) 
AH109 Yeast was transformed with pGBT9/pGAD10 plasmids containing the indicated 
constructs and spotted onto High stringency selection (SD-LWHA+X-α-gal) agar as serial (1:10) 
dilutions (top to bottom). LMO4 in pGBT9 against the test LIDs in pGAD10 are positive controls 
and the empty plasmids in both pGBT9 and pGAD10 are negative controls.  
 
To begin research for this thesis, the Y2HCA experiments with the previously generated 
constructs (Figure 3.1) were repeated (Figure 3.2). The top panel in Figure 3.12B reports the 
direct interaction between LMO4 and the test LID. Robust yeast growth and blue colour 
indicate a strong interaction for with the test LIDs except LID9, which showed less yeast 
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growth. The top panel in Figure 3.2 shows a set of positive controls for this experiment as 
LMO4 was previously demonstrated to bind to all the test LIDs (M. Petitmangin, unpublished 
data). The subsequent panels report the ability of the same test LIDs to bind M1-LMO4 and 
M2-LMO4, respectively. In these cases the test LID must successfully compete with M1 and 
M2 for binding to LMO4. For M1-LMO4 there is a solid blue circle reporting robust yeast 
growth and α-galactosidase activity for the first dilution spot indicating that M1 has been 
displaced by LMO4. There are a few spots present for the next two dilution spots. M2 was 
also displaced by LMO4 as evidenced by the solid blue circles for the first dilution point (same 
as M1) but then an almost complete circle of growth for the 2nd dilution spot and spots for 
the final dilution spot. It was noted that compared to LMO4 alone, and to a lesser extent M1-
LMO4, M2-LMO4 shows a greater level of blue yeast.  However, all the test LIDs appeared to 
bind equally well to M1-LMO4 or to M2-LMO4. These observations indicate that the M1 and 
M2 mutant constructs bind LMO4 too weakly to be useful in the Y2HCA as LIDs are required 
that  bind LMO4 weakly enough to be displaced by some test LIDs but strong enough to resist 
others. Since neither M1 no M2 fulfil the requirements for this system, new constructs were 
needed. The development and testing of such alternative constructs follows. 
3.1 Designing the new CtIP mutants  
M1 and M2 are consecutive triple alanine mutants of CtIP where the mutations lie in the 
region of CtIP (664-675) that contacts the hydrophobic binding pocket in LMO4LIM1. These 
were previously shown to abrogate binding in Y2H assays (22). As these mutants bound LMO4 
too weakly to be of use in the Y2HCA, new mutants were chosen for testing. The first is a triple 
alanine mutation D674A/T675A/K676A (M3) that was previously shown to have a smaller 
effect on LMO4-CtIPLID binding (22, 83) A further three single mutants (M668A, D669A, and 
V670A) were designed that should have a smaller effect on LMO4-binding than the original 
triple mutants (M1: M668A/D669A/V670A and M2 T671A/V672A/I673A and M2). 
 
 
 
45 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: CtIP Mutant Constructs. (A) Schematic representation of previous and new CtIP 
mutant constructs tethered to LMO4 by a flexible 11-residue linker. (B) Structure showing 
LMO4 (blue, ribbon structure) binding to CtIP (sticks and ribbon structure) with residues 
mutated to alanine M3 (light pink), residues mutated in M1 (hot pink), residues mutated in 
M2 (green) as indicated. Residues that were mutated in the single alanine versions of M1 
were V670A (dark green), D669A (bright green) and M668A (light green). The remainder of 
the CtIP binding region is shown in orange. Image generated in PyMOL from PDB 2L4Z (22).  
 
The triple alanine mutant M3 was sub-cloned into a pGBT9 plasmid tethered to LMO4 (Figure 
3.3 A) using Gibson Assembly (Section 2.2). The single alanine mutants (Figure 3.3A) were 
generated and cloned into pGBT9 plasmids using mutagenic primers, overlap extension and 
Gibson Assembly (Section 2.2).  
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46 
 
3.2 M3, M668A, D669A and V670A in Y2HCA 
The new M3 (Figure 3.5), M668A, D669A and V670A constructs (Figure 3.4) were tested in the 
Y2HCA.  
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Y2HCA for CtIP-LMO4, M668A-LMO4, D669A-LMO4 and V670A-LMO4 against test 
LIDs. AH109 Yeast was transformed with pGBT9/pGAD10 plasmids containing the indicated 
constructs and spotted onto low stringency selection (SD-LWH+0.5 mM 3AT+X-α-gal) agar as 
serial (1:10) dilutions (top to bottom). (B) Transformation controls comprise AH109 Yeast 
transformed with pGBT9/pGAD10 plasmids containing the indicated constructs and spotted 
onto control media (SD-LW) agar as serial (1:10) dilutions (top to bottom). 
 
The data for M668A-LMO4, D669A-LMO4 and V670A-LMO4 (Figure 3.4A) showed that these 
constructs were indistinguishable from CtIP-LMO4. In all experiments yeast growth was 
present at all three dilutions for DC4 with the reporter constructs, but no significant amounts 
of yeast growth were seen for the other LIDS. These data suggest that DC4, but no other test 
LID, was able to displace all four CtIPLID variants in the tethered constructs. The lack of blue 
colour suggests a relatively weak interaction as only the one of the reporter genes (selecting 
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for yeast growth) is being activated, while that for α-galactosidase (to produce blue colour in 
the presence of α-X-gal) is not being activated. As the single alanine mutants behaved the 
same as CtIP in this assay they are not useful additions to the Y2HCA, as they are unlikely to 
provide additional information about relative binding affinities. 
 
 
 
 
 
 
 
 
Figure 3.5 Y2HCA for M3-LMO4 against test LIDs. (A) AH109 Yeast was transformed with 
pGBT9/pGAD10 plasmids containing the indicated constructs and spotted onto High 
stringency selection (SD-LWHA+X-α-gal) agar as serial (1:10) dilutions (top to bottom). LMO4 
in pGBT9 against the test LIDs is a positive control and the empty plasmids in both pGBT9 and 
pGAD10 are negative controls. (B) Transformation controls, comprising AH109 Yeast 
transformed by pGBT9/pGAD10 plasmids containing the indicated constructs and spotted 
onto control media (SD-LW) agar as serial (1:10) dilutions (top to bottom). 
 
The data for M3-LMO4 (Figure 3.5A middle panel) showed robust yeast growth and blue 
colour for interactions with DC4, and less growth for LID2, LID3 and LID6. No growth was 
observed for interaction with LID9, suggesting that only this LID was unable to displace M3 to 
bind LMO4. The transformation controls (Figure 3.5B) indicated that lack of yeast growth on 
the interaction plate (Figure 3.5A) was not caused by errors in co-transformation. These data 
indicate that M3-LMO4 is a useful addition to the Y2HCA, as it can distinguish the relative 
binding affinities of weak LIDs.  
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3.3 Chapter Discussion  
The previous CtIP mutants from my Honours research (M1-LMO4 and M2-LMO4) were 
tested in the Y2HCA, where they were displaced by all the test LIDs. The more robust yeast 
growth seen for M2-LMO4, and to a lesser extent M1-LMO4, compared to LMO4 (Figure 3.2) 
could represent a stronger interaction. However, Y2H experiments can be affected by 
factors such as stability of the constructs used. As M2-LMO4 shows more robust yeast 
growth with all the tests LIDs than does LMO4 alone, there may a stabilising effect 
associated with M2 and M1 that makes it easier for the LID to bind to LMO4. That is, a weak 
interaction between LMO4 and M1/M2 may be sufficient to prevent the aggregation of 
LMO4 making more protein available to bind the test LID in the assay. These fusion 
constructs could be useful for detecting the interaction of very weak interactions with LMO4 
in Y2H. 
Four more CtIPLID mutant constructs (M3-LMO4, M668A-LMO4, D669A-LMO4 and V670A-
LMO4) were designed and tested in the Y2HCA. The triple alanine mutant was displaced by 
all test LIDs except one and thus could provide some estimation of relative binding affinities. 
The single alanine mutants were too similar to CtIPLID, and bound too strongly to LMO4, to 
be displaced by the test LIDs. In the single alanine experiments there were small differences 
in colour production by the yeast, with some yeast growth appearing white rather than 
blue. The small differences in colour production alone (Figure 3.4) are not a good indicator 
of absolute binding affinity, as illustrated by the fact that interactions with LMO4 only 
(Figure 3.4A, top panel) show highest levels of blue colour for LID3 in this experiment, but 
the Y2HCA assay indicates that DC4 is the tightest binder, which is supported by biophysical 
experiments (M. Petitmangin and P. Stokes, unpublished data) to assess relative binding 
affinity.   
This work added a new tethered construct (M3-LMO4) to the Y2HCA repertoire to help 
distinguish between the relative binding affinities of test LIDs. Figure 3.6 shows the new 
range of tethered constructs that can be used to validate and assess the relative binding 
affinity of an α-helix identified by the high-throughput EGFP complementation screen 
(Chapter 4).  It may still be desirable to add additional constructs that help to distinguish 
weaker binders (Figure 3.6). Given that most of the triple alanine mutants were too weak 
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(Figure 3.2) and single alanine mutants (Figure 3.5) were too strong, double alanine mutants 
of CtIPLID might form useful CtIP variants that can be displaced by some, but not all, test 
LIDs.  
 
Figure 3.6: New range of tethered complexes to be used in Y2HCA  
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Chapter 4: High through-put EGFP complementation system 
This chapter continues the development of a split EGFP complementation system to identify 
α-helical peptides that bind to LMO4 (Section 1.2.3). Previously, as part of an Honours 
research project (G. McClymont, Honours Thesis in Biochemistry, The University of Sydney, 
2017) constructs for use as positive controls based on the tightly-binding natural binding 
partner LDB1 were developed and produced high levels of fluorescence. Constructs for use as 
negative controls that were created using a random peptide, the negative controls, were 
largely insoluble and produced very low levels of fluorescence. The controls were validated 
by the quantification of their whole cell fluorescence when overexpressed in E. coli. The 
system was further developed to be capable of screening peptides that vary only in their 
ability to bind LMO4LIM1. An additional fluorescent protein (mCherry) was added to the system 
in an attempt to provide an expression control.  
4.1 Previous work on a high through-put split EGFP 
complementation system 
Prior to the start of this project, four control constructs, Positive 36, Positive 45, Negative 36 
and Negative 45 (Figure 4.1) were created and use to transform BL-21 (DE3) E. coli cells for 
expression (84) (Section 1.2.4.1). Fluorescence was assessed using bulk fluorescence for the 
soluble fractions (Figure 4.2) and by eye for whole cells in ambient light (Figure 4.3).  
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Figure 4.1 Split EGFP Control Constructs. The N-terminal fragment (EGFP-A) is tethered to 
LMO4, and the EGFP C terminal fragment (EGFP-B) is tethered to (A) a 36-residue fragment 
of LDB1 (residues 295-330) and is termed Positive 36; (B) a 36-residue Random peptide #1 
and is termed Negative 36; (C) a 45-residue fragment of LDB1 (residues 295-339) and is 
termed Positive 45; and, (D) Random peptide #1 45 residues (the first 36 residues are the 
same as Negative 36 with nine additional random residues).  
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Figure 4.2: Fluorescence emission spectra of spEGFP control constructs. Positive 36, Positive 
45, Negative 36 and Negative 45 were overexpressed in BL-21 (DE3) cells, 18 h 20 °C, the 
soluble fractions obtained, and fluorescence emission spectra measured. Fluorescence 
intensity at 400 v (excitation at 480 nm and emission spectra from 495–570 nm), was 
normalised for cell density by dividing the intensity by absorbance at 600 nm. The maximum 
emission peak wavelength of EGFP is 510 nm.  
 
The normalised fluorescence spectra for Positive 36 and Positive 45 were essentially identical, 
with a maximum fluorescence at 510 nm, which is consistent with the theoretical maximum 
52 
 
for EGFP (Figure 2.2). In comparison, the soluble fractions of the negative controls, Negative 
36 and Negative 45 had very low levels of fluorescence. These data demonstrated that 
Positive 36 and Positive 45 may by useful fluorescing positive controls, and that Negative 36 
and Negative 45 should be suitable non-fluorescing negative controls.  
 
 
Figure 4.3: Ambient light image of resuspended whole cells. Resuspended whole cell 
samples of (A) split EGFP, (B) Positive 36, (C) Positive 45, (D) Negative 36 and (E) Negative 45, 
grown and induced in E. coli at 20 °C. Samples were normalised for a cell density of 1 at 
OD600nm.  
As the intention was to use whole cell fluorescence to screen for peptides binders, whole cell 
expression samples of these constructs were examined (Figure 4.3). The green colour visible 
in the whole cell resuspensions of Positive 36 and Positive 45 under ambient light conditions 
is a good indication that the fluorescence would be detectable in whole cell samples. The lack 
of green colour in the Negative 36 and Negative 45 samples was similarly a good indication of 
no or low fluorescence. By ambient light there appeared to be a difference between Negative 
36 (Figure 4.3D) and Negative 45 (Figure 4.3E). However, according to Figure 4.2 there was 
no significant difference between them. These potential discrepancies were not resolved 
during my Honours project work. 
4.2 Whole cell fluorescence analysis of previous constructs 
For this thesis a first step was to reassess the whole cell fluorescence of the different 
constructs. This was carried out using a fluorescence plate reader, which offered several 
advantages. Firstly, the plate reader allows samples to be shaken before measurement. This 
is important for whole cells as they can quickly settle to the bottom of the well/cuvette and 
thus affect the reading. Even if settling occurs the sample is measured by an excitation beam 
A B C D E 
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from the top of the well and the emitted light is reflected back through the body of the sample 
(rather than across a cuvette) minimising errors in measurement.  The temperature control 
of the fluorometric plate reader enables rapid cooling to 4 °C, which is the desired 
temperature for preserving cells resuspended in PBS. Thirdly, the plate reader allows rapid 
assessment of 96 samples all under the same experimental conditions.   
The previous experiments (Figures 4.2 and 4.3) were carried out using BL-21 (DE3) cells at 20 
°C. In order to find the optimal E. coli strain and temperature for expression of the spEGFP-
LMO4 constructs for whole cell fluorescence measurements, two cell strains and 
temperatures were trialled (Figure 4.4). Lower expression temperatures have been previously 
implicated in promoting LIM domain solubility (20) and the choice of cell type can affect levels 
of expression (85).  
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Figure 4.4: Fluorescence at 507 nm of E. coli cells overexpressing the LMO4 constructs. Blue 
circles represent BL-21 (DE3) cells at grown at 20 °C for 18 h. Green squares represent BL-21 
(DE3) cells at grown at 25°c for 18 h. Red triangles represent Rosetta 2 cells at grown at 20 °C 
for 18 h. Purple diamonds represent Rosetta 2 cells at grown at 25 °C for 18 h. The shades of 
colour indicate biological replicates (N = 3), with 1 or 3 technical replicates. Bars represent 
the mean values of all replicates. Data were obtained using a fluorescence plate reader, 
excitation 482-454 nm and emission 504-517nm (Section 2.4.2). Samples were normalised for 
a cell density of 0.3 at OD600nm.  
 
In terms of cell type, for each construct/temperature combination, there was little overall 
difference in fluorescence measured. The only exception was for increased variation for one 
54 
 
the positive controls at 20 °C, where the fluorescence of one biological replicate was relatively 
high and two others relatively low. Based on these results, the BL-21 (DE3) cells were used in 
subsequent experiments. In terms of temperature, essentially all constructs showed higher 
levels of fluorescence when expressed at 20 °C rather than at 25 °C, and the overall difference 
in fluorescence between the negative and positive controls was higher at 20 °C. 
Ideally, the combination of expression conditions and constructs should be where the 
negative control has the least fluorescence (background fluorescence) and the positive 
control has the highest fluorescence, creating a large dynamic range with which to detect 
improved fluorescence. Negative 36 gave the lowest fluorescence across all strains and 
conditions and the corresponding Positive 36 had a significantly higher fluorescence than 
Negative 36 for all conditions. Although the fluorescence of Positive 45 was the highest for all 
constructs, the levels of Negative 45 fluorescence meant that the difference of fluorescence 
between the pairs of negative and positive constructs is equivalent. The 36-residue constructs 
were considered a better option because they showed less negative control/background 
fluorescence. Note that the 295-330 region of LDB1 used in the Positive 36 construct is 
sufficient for binding to LMO4, as previously determined by Y2H and assessment of the LMO4-
LDB1 structure (19). The longer peptide LDB1 Positive 45 (LDB1 295-339) contains an 
additional 9-residue acidic region that was at one point defined as being part of LDB1LID, and 
appears to confer increased solubility LIM-LID constructs. In summary, the 36-residue 
variants, expressed in BL-21 (DE3) E. coli cells at 20 °C appear to be optimal for further 
development.  
4.3 Validating whole cell fluorescence 
Two orthogonal methods were used to validate the fluorescence in the BL-21 (DE3) cells. The 
first was flow cytometry, which is important as the goal is to screen libraries using FACS. Flow 
cytometry lacks the cell sorting capability of FACS but has the same analytical capacity and 
was a more convenient method for testing at this stage of the project. Although not necessary 
for analysis, the cells were fixed with paraformaldehyde (see section 2.1.3) prior to analysis, 
to prevent possible bacterial contamination of mammalian cells on the in-house instrument. 
The 36-residue constructs were subjected to flow cytometry alone, and together in known 
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ratios, to establish if different populations could be identified and separated using lasers and 
filters common to Flow cytometry and FACS. 
 
 
 
 
 
 
 
Figure 4.5: EGFP fluorescence of BL-21 (DE3) cells with Positive 36 and Negative 36. BL-21 
(DE3) cells at grown at 20 °C for 18 h overexpressing either Positive 36 or Negative 36. Cells 
were fixed in PBS with 4% paraformaldehyde.  In each experiment 2 × 105 cells were counted. 
(A) Negative 36 (B) Positive 36 (C) 1:1 ratio of positive 36 and negative 36. Figures were 
created using FlowJo. 
 
The pseudocolour plots in Figure 4.5 use side-scatter (Y-axis) to assess cell size and EGFP 
fluorescence (X-axis) to characterise populations of cells. Panels A and B show Negative 36 
and Positive 36, respectively. Each produces a population of cells that is fluorescent, with 
Positive 36 being significantly (~10-fold) more fluorescent than Negative 36. The small scatter 
of signals at ~102 on the X-axis represents a small number of cells (less than 8% of the total 
population) that are not expressing EGFP. In Figure 4.5 C, equal amounts of cells expressing 
each construct were detected, showing the ability of the flow cytometer to distinguish these 
populations. These data suggest that these constructs are appropriate for a FACS system.  
A B C 
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Figure 4.6: Fluorescence microscopy of Positive 36 and Negative 36. BL-21(DE3) E. coli cells 
overexpressing constructs (A) Positive 36 and (B) Negative 36 were for 18 h at 20 °C. Live cells 
were resuspended in PBS, normalised for cell density of 0.3 OD600nm and visualised by 
fluorescent microscopy for 1.4 s. The scale bar is 10 µm.  
Fluorescence microscopy was also used to validate the whole cell fluorescence. Figure 4.6A 
shows Positive 36 expressing cells. The many white dots represent fluorescent cells. 
Conversely, for Negative 36 (Figure 4.6B) no fluorescent cells can could be seen. This 
corroborates the data from fluorimetry and flow cytometry (Figures 4.4 and 4.5) 
demonstrating that the split EGFP system produces fluorescence that is visible in whole E. coli 
cells upon the protein-protein interaction facilitated interaction of the two split EGFP sections 
shown in Figure 4.1.  
4.3 New split EGFP constructs  
LMO4 is modular, made up of two tandem LIM domains (section 1.2.1), each of which binds 
to a region of LDB1. Thus, in terms of screening the library it should be possible to screen 
against each LIM domain separately in the context of a larger interaction interface. This is 
beneficial for two reasons. First it decreases the size of the region in the peptide binding 
target. This is beneficial as it should require shorter peptides for randomisation and screening, 
which reduces the size of the library. Second, by leaving one binding module of LDB1 intact, 
we maintain some ability to bind LMO4. Only a small positive binding event from the α-helical 
peptide will be required to increase fluorescence and enable detection. In contrast, a truly 
naïve library would most likely be populated with weak binders and it would be challenging 
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to find hits strong enough to detect. We decided to begin with targeting the LIM1 region of 
LMO4 (LMO4LIM1), which required some modifications to the construct design.  
 
 
 
Figure 4.7 Split EGFP constructs for screening α helices against LMO4 LIM1. The N-terminal 
fragment (EGFP-A) is tethered to LMO4, and the EGFP C-terminal fragment (EGFP-B) is 
tethered to LDB1 LIM2 binding region and the α-helical peptide. 
 
In this design the LIM2 binding portion of LDB1 (Figure 4.7) is maintained to bind LMO4LIM2 
and bring LMO4LIM1 close to the introduced α-helix.  However, an important consideration 
was at what point LDB1 should switch to the α-helix? The structure of LDB1 bound to LMO4, 
along with a series of other LIM-LID complexes and mutagenic studies, indicates that residues 
299-311 of LDB1 contact LIM2, residues 318-327 contact LIM1, and residues ~312-317 form 
a spacer region between the two binding modules (19-21). Interestingly, residues 316-318 
show some helical characteristics which was reported in terms of the secondary structure 
assessments from the NMR data (19) (Figure 4.8B) that might serve a helix-capping function, 
facilitating the folding of introduced helices. Thus, it was decided to test the replacement of 
two lengths of LDB1, from 315 (eliminating most of the spacer) and from 318 (leaving the 
putative helix capping residues in place). Note that even if the extra residues in the latter 
version don’t promote helical structure, they could allow some flexibility between the native 
β-strand and the introduced helix, thus eliminating steric hindrance and promoting helix 
formation. Random peptide #2 and #3 are different random peptides generated using 
Sequence Manipulation Suite (86). The use of 3 different random peptides in the constructs 
so far is to ensure that data for the constructs with random peptides are not biased by a 
specific randomly generated sequence.  
If LDB1-LMO4LIM2 binding is too high in the context of these constructs, background 
fluorescence could be too high to detect positive binding helices. To control for this possibility, 
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a V303A mutation was made to the LIM2 binding module of LDB1, as this mutation had been 
previously shown to decrease the affinity of LDB1 for LMO4LIM2 (19).  
 
Figure 4.8 New Split EGFP Constructs. (A) The N-terminal fragment (EGFP-A) is tethered to 
LMO4, the EGFP C-terminal fragment (EGFP-B) is tethered to (1) Positive 36 (from Figure 4.1) 
(2) LDB1 295-318 and Random peptide #2 (R#2), and is termed LDB1 318; (3) LDB1 V303A 
295-318 and Random peptide #2 (R#2), and is termed LDB1 318 mutant; (4) LDB1 295-315 
and Random peptide #3 (R#3), and is termed LDB1 315; (5) LDB1 V303A 295-315 and Random 
peptide #3 (R#3), and is termed LDB1 315 mutant; (6) Negative 36 (from Figure 4.1). A short 
flexible linker (L) connects LMO4 to 1-6. (B) Cartoon structures of new constructs 2-5. LMO4 
is blue, LDB1 is yellow, Random peptide #2 is orange, Random peptide #3 is burnt orange and 
mutation V303A is red (linker is not shown). Images were generated in PyMOL from PDB 1RUT 
(21).  
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4.4 Fluorescence analysis of new constructs 
 
 
Figure 4.9 Whole cell fluorescence at 507 nm of E. coli cells expressing the new constructs. 
(A) Relative Fluorescence of Constructs 1-6 as compared to Construct 1. (N = 3 with 3 technical 
replicates in each experiment). Samples were normalised to a cell density of 0.3 at 0D600nm (B) 
Reference schematics of constructs expressed.   
 
In Figure 4.9A the bulk fluorescence properties of each sample were expressed relative to 
that of Construct 1 in each experiment to control for experimental variance of fluorescence. 
Constructs 2 and 3 showed almost identical levels of fluorescence that were just above that 
of the negative control, suggesting that the longer 318 variants could be suitable constructs 
for screening LMO4LIM1-binding peptides. Constructs 4 and 5, however, showed levels of 
fluorescence that were much closer to the positive control. For the 318 constructs the V303A 
mutation had no measurable effect, and for the 315 constructs the mutant appears to have 
slightly reduced fluorescence.   
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Figure 4.10: Flow cytometry histogram of 6 split EGFP constructs. (A) BL-21 (DE3) cells  grown 
at 20 °C for 18 h overexpressing each of the constructs 1-6. Cells were fixed in PBS with 4% 
paraformaldehyde. Samples containing 2 × 105 cells expressing each of the constructs 1-6 
were combined and subjected to flow cytometry. The construct expression contributing to 
the peaks are labelled and are based on data for each individual construct. Fluorescence 
histogram created with FlowJo (B) Reference schematics of constructs expressed.  
 
The samples were also subjected to Flow Cytometry, as individual samples (not shown) and 
mixtures of all samples (same number of cells from each sample; Figure 4.10A). Under these 
conditions, the 315 constructs and Positive 36 are indistinguishable. The 318 constructs form 
the middle peak, which can be distinguished from the small peak from Negative 36. No 
significant differences were detected between the mutant and wild-type constructs. 
The small increase in fluorescence for the 318 constructs can be assumed to arise from the 
binding of LMO4LIM2 to LDB1 in the constructs. It is more observable in the flow cytometry 
experiments (Figure 4.10) than the bulk fluorescence experiments (Figure 4.9) because of the 
log scale in the representation of the Flow cytometry data. 
Based on these data, the construct chosen for further screening for α-helical peptides against 
LMO4LIM1 was Construct 2, LDB1 318. It was decided to try some test α-helices in the system 
to see if non-specific binding of sequences is a common problem or a rare artefact (Chapter 
5). A means to control for overall expression levels is described in the next section. 
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4.5 Introduction to mCherry 
It was decided to introduce a second fluorescent protein under the control of the same 
promoter as an expression reporter (Section 1.2.4). mCherry was chosen for this purpose 
because its fluorescence properties are reportedly distinguishable from those of EGFP (56). A 
ratio of green to red fluorescence should be a more accurate measure of binding affinity than 
EGFP fluorescence only as it normalises for expression levels in the cell.  The introduction of 
mCherry made it necessary to switch from a pET15b vector to a pETDuet vector (Figure 4.11).  
 
 
 
 
 
 
 
 
Figure 4.11: pETDuet with split EGFP and mCherry. The split EGFP is shown in the first 
multiple cloning site and mCherry is in the second multiple cloning site. Both are under the 
control of a T7 promoter.  
 
pETDuet has two multiple cloning sites, each under the control of a T7 promoter, allowing the 
simultaneous expression of two different proteins. The split EGFP construct was cloned into 
multiple cloning site one, whilst mCherry was introduced into multiple cloning site two.  
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4.6 Testing mCherry  
Attempts to clone all the split EGFP constructs into pETDuet with mCherry were made 
However, this cloning was difficult due to the low copy number of pETDuet vectors, and the 
need to use restriction enzymes with different efficiencies. At the end of the time available 
for this project, three constructs had been successfully cloned:  mCherry only, as well as 
spEGFP and LDB1 318 with mCherry (Figure 4.12).  
 
 
 
 
 
 
Figure 4.12: Schematic representations of split EGFP and mCherry constructs. (A) New 
construct, mCherry alone  termed mCherry (B) Pre-existing split EGFP alone, termed spEGFP, 
(C) New construct, split EGFP and mCherry, termed spEGFP + mCherry. (D) Pre-existing LDB1 
318, (E) LDB1 318 and mCherry, termed LDB1 318 + mCherry.  
 
BL-21 (DE3) cells were transformed by constructs A-E and expression induced (Section 2.4). 
The EGFP and mCherry fluorescence of constructs A-E (Figure 4.12) were measured using 
plate fluorimetry (Figure 4.13) and flow cytometry (Figure 4.17). The emission wavelength for 
mCherry is 600 nm, which is the same wavelength traditionally used for measuring the optical 
density of cells. The cell density of cells expressing mCherry can be underestimated by up to 
10% using OD600nm, but measuring all cell densities at 700 nm eliminates this problem (87).  
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Figure 4.13: Whole cell EGFP and mCherry fluorescence of E. coli cells expressing the new 
mCherry constructs. Fluorescence of constructs as labelled (N = 3 with 3 technical replicates 
in each experiment). Samples were normalised to a cell density of 0.2 at 0D700nm. Fluorescence 
of EGFP was measured by excitation at 484 nm and emission at 507 nm. Fluorescence of 
mCherry as measured by excitation at 587 nm and emission at 610 nm.  
 
As expected, cells that did not contain an mCherry construct (spEGFP and LDB1 318) showed 
no fluorescence at 600 nm, and cells that did not contain EGFP (mCherry) showed no 
fluorescence at 507 nm (Figure 4.13).  Levels of mCherry fluorescence in the cells expressing 
the mCherry and spEGFP + mCherry constructs were the same, but considerably lower (~65%) 
in the cells expressing the LDB1 318 + mCherry construct.  If mCherry is a good control for 
overall expression levels, this data indicates that the overall cellular expression levels in LDB1 
318 + mCherry expressing cells are lower than that of the other two constructs. However, 
there was a significant difference in EGFP fluorescence between the cells expressing spEGFP 
only and spEGFP + mCherry constructs, whereby spEGFP + mCherry was decreased to ~15% 
of the spEGFP only. In contrast, the level of EGFP signal is the same for cells expressing LDB1 
318 and LDB1 318 + mCherry. The level of mCherry fluorescence in cells expressing mCherry 
only, and in spEGFP + mCherry are also the same.  
If we did assume that mCherry is a good expression reporter for this system, we would 
compare the ratios of EGFP:mCherry fluorescence and use that as a reporter of binding. At 
this stage we can only compare cells expressing spEGFP + mCherry and LDB1 318 + mCherry, 
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and those data indicate no significant change, despite EGFP being a positive control and LDB1 
318 being a negative control (Figure 4.14).  
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Figure 4.14: Ratio of EGFP: mCherry Fluoresence for spEGFP + mCherry and LDB1 318 + mCherry.  
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Figure 4.15: Pseudo colour dot plots measuring EGFP and mCherry fluorescence. BL-21 (DE3) 
cells at grown at 20 °C for 18 h overexpressing constructs A-E from Figure 4.11. Cells were 
fixed in PBS with 4% paraformaldehyde.  In each experiment 1 × 105 cells were counted. 
Fluorescence of EGFP was measured by excitation at 480-90 nm and emission at 500-10 nm. 
Fluorescence of mCherry as measured by excitation at 580-90 nm and emission at 600-10 nm. 
(A) spEGFP (31% non-fluorescing), (B) mCherry (52% non-fluorescing), (C) spEGFP + mCherry 
(18% non-fluorescing), (D) LDB1 318 (10% non-fluorescing) and (E) LDB1 318 + mCherry (3% 
non-fluorescing). Images generated in FlowJo.  
 
One of the replicates from each experiment in Figure 4.13 was analysed using flow cytometry 
(Figure 4.15). These data indicated a large range in the sample populations that did not 
express fluorescent protein (Figure 4.15 boxed). In particular, for spEGFP, mCherry and 
spEGFP + mCherry (Figure 4.15A-C) 20-50% of cells did not express fluorescent protein. 
Variation in levels of fluorescent protein expression was seen to a much smaller extent in 
previous experiments (Figure 4.5). For further analysis (Figure 4.16) the non-fluorescing cells 
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spEGFP spEGFP + mCherry mCherry 
LDB1 318 LDB1 318 + mCherry 
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identified here were excluded, which meant that while equal amounts of cells were not being 
compared, relative differences in cell populations can still be observed.  
 
Figure 4.16: Flow cytometry histograms measuring EGFP and mCherry Fluorescence. BL-21 
(DE3) cells at grown at 20 °C for 18 h overexpressing constructs A-E from Figure 4.11. Cells 
were fixed in PBS with 4% paraformaldehyde.  In each experiment 1 × 105 cells were counted. 
Fluorescence of EGFP was measured by excitation at 480-90 nm and emission at 500-10 nm. 
Fluorescence of mCherry as measured by excitation at 580-90 nm and emission at 600-10 nm 
Fluorescence histograms were generated and overlayed using FlowJo. The constructs shown 
are spEGFP (green), mCherry (red), spEGFP + mCherry (dark blue), LDB1 318 (cyan) and LDB1 
318 + mCherry (pink).  (A) spEGFP, mCherry and spEGFP + mCherrry (B) mCherry, LDB1 318 
and LDB1 318 + mCherry (C) spEGFP, mCherry,  spEGFP + mCherrry, LDB1 318 and LDB1 318 
+ mCherry . (D) spEGFP, mCherry and spEGFP + mCherry (E) mCherry, LDB1 318 and LDB1 318 
+ mCherry (F) spEGFP, mCherry,  spEGFP + mCherry, LDB1 318 and LDB1 318 + mCherry. 
Histogram colours are true to the key in the non-overlapped regions.  
 
A B C 
D E F 
= spEGFP = mCherry = spEGFP + mCherry = LDB1 318 = LDB1 318 + mCherry 
67 
 
Cells expressing spEGFP (Figure 4.16A) had the highest level of EGFP fluorescence. There was 
a dramatic decrease (~10x) in EGFP fluorescence when mCherry was also being expressed 
(Figure 4.16A). A much smaller reduction (~4 x) of EGFP fluorescence upon mCherry addition 
was observed between cells expressing LDB1 318 and LDB1 318 + mCherry constructs (Figure 
4.16B).   
There was an obvious problem associated with mCherry expression (Figure 4.16D-F), as all 
the samples, regardless of whether or not they carried an mCherry expression construct or 
had undetectable expression by plate fluorimetry (Figure.12), had a mCherry fluorescence 
peak. Unfortunately, the setup used to collect the data in Figure 4.16 does not appear to be 
optimised for simultaneous EGFP and mCherry fluorescence in E. coli, so there is no reliable 
way to accurately quantify mCherry fluorescence from this data.  
4.7 Conclusion and Future Directions  
In this chapter a split EGFP complementation system for use in E. coli cells was modified to be 
suitable for screening a library of α-helical peptides against LMO4LIM1. Four constructs (LDB1 
318, LDB1 318 mutant, LDB1 315 and LDB1 315 mutant) were tested. The LDB1 318 construct 
was selected for library screening because it showed the lowest levels of background EGFP 
fluorescence as measured by plate fluorimetry and flow cytometry, and provided a large 
dynamic range for selection of binders. LDB1 318 may also help induce helicity through the 
inclusion of LDB1 residues that have helical properties.  The LDB1 315 and LDB1 315 mutant 
construct had unexpectedly levels of high fluorescence as it was assumed that constructs with 
three extra LDB1 residues might increase the binding of the 318 constructs as compared to 
the 315 constructs. The two most plausible explanations for this observation are as follows. 
First, the LDB1 315 constructs had a higher level of expression within the cell than LDB1 318 
and thus the cells had higher fluorescence due not to increased binding but rather to 
increased copy number. Second, the sequence in Random #3, the part of LDB1 315 that comes 
into contact with LMO4LIM1, could be biased towards binding LMO4LIM1. The sequence of 
Random #3 is KANTMTLMPIPAVYR, where the red highlighted residues are all hydrophobic. 
The red hydrophobic region could bind to the hydrophobic peptide-binding surface of 
LMO4LIM1 when brought into proximity by LDB1 binding to LMO4LIM2. Although this could be 
high affinity binding, it is unlikely to represent specific binding, as was shown previously for 
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the scrambled ISL1LID binding to the LIM domains of LHX3 (80). In contrast, the sequence of 
Random#2 in LDB1 318 is AKQLATAAISMC, which is shorter, has fewer bulky hydrophobic 
residues and a shorter stretch of hydrophobic residues than Random#3. By testing some α-
helices in the LDB1 318 construct we can better assess if the LDB1 315 high result is a common 
problem or rare artefact. Chapter 5 continues with the design of α-helical libraries and testing 
binding of template α-helices in place of the Random peptide sequences.  
Three constructs with fluorescent protein mCherry were tested in an attempt to create an 
expression control. EGFP and mCherry fluorescence was measured via plate fluorimetry and 
flow cytometry. For both methods it was observed that the EGFP signal decreased (to varying 
degrees) with the addition of mCherry. A possible explanation for this phenomenon is that 
the cells may be unable to express spEGFP and mCherry in equal amounts, despite the use of 
the bicistronic expression system, and/or there may be a maximum capacity for 
overexpression and correct folding of these proteins that favours mCherry at higher levels of 
expression. Attempts were made to assess the same cells used for plate fluorimetry and flow 
cytometry on SDS-PAGE to visualise the expression levels of EGFP and mCherry. However, the 
fixing of the cells for flow cytometry meant their migration on SPS-PAGE was affected, and no 
distinct protein bands were able to be seen. 
The mCherry levels measured by flow cytometry were similar for all samples regardless of the 
presence of a mCherry protein (Figure 4.16D-F). The cause of this may be a bleed-through of 
the strong fluorescence of EGFP or intrinsic E. coli proteins that emit at around 610 nm. 
However, it is plausible that in a more sophisticated Flow Cytometer or FACS machine with 
more appropriate filter sets for excitation and emission this type of bleed-through could be 
substantially reduced or eliminated.  
From the limited number of constructs tested in Figures 4.13-15 mCherry does not appear to 
be a useful expression control the split EGFP system because of variable expression levels of 
the two fluorescent proteins when used in combination. However, additional constructs with 
combinations such as those shown in Figure 4.17 should be tested before it is decided which 
construct design to use in screening the peptide library. In addition, unfixed cells should be 
analysed by SDS-PAGE to assess the relative levels of mCherry and EGFP expression.  
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Figure 4.17: Additional split EGFP and mCherry constructs. (A) Positive 36 and mCherry, 
termed Positive 36 + mCherry. (B) LDB1 315 and mCherry, termed LDB1 315 + mCherry, (C) 
New construct, split EGFP and mCherry, termed spEGFP + mCherry. (D) Pre-existing LDB1 318, 
(E) LDB1 318 and mCherry, termed LDB1 318 + mCherry.  
 
While it may be suitable to look for an alternative expression control, the split EGFP system 
can operate without one. It may be appropriate to select a larger pool of fluorescing cells by 
FACS and to select from smaller libraries than might otherwise be the case.  However, 
validation will be even more important, so that the Y2HCA (Chapter 3) and other binding 
assays will be particularly useful.  
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 Chapter 5: Library Design 
In Chapter 4 I developed a split EGFP complementation system to screen peptides for binding 
to LMO4LIM1 in the context of a split EGFP tethered LMO4-LDB1 construct. The LDB1 318 
construct was selected for screening. The next step was to test naturally occurring α-helices 
in this system that could be potentially used as the template α-helix for the library. This 
Chapter looks at the process by which three candidate α-helices were chosen, and the result 
of adding these template peptides to the split EGFP system.  
To ensure the full diversity of a large library is represented in the cells being screened we 
need a very efficient transformation method. This Chapter recounts experiments to optimise 
the chemical transformation method to maximise transformational efficiency.  
It is intended that FACS will be used to isolate cells with higher levels of fluorescence, and the 
plasmid DNA from the selected cells will be sequenced to identify candidate binders. This 
Chapter describes efforts to optimise high quality plasmid extraction from E. coli cells that 
had been previously optimised for overexpression of proteins.   
5.1 α-helix template candidates and initial selection criteria  
A preliminary set of 15 pre-existing α-helices (Table 5.1) were selected by mining the 
literature for naturally occurring α-helices for which structures had been solved. Specifically, 
α-helices were identified that were involved in protein-protein interactions and had 
previously been successfully manipulated through protein engineering. These criteria 
increase the likelihood of the helix being sufficiently malleable in the context of a library. The 
α-helix should be able to bind the hydrophobic groove on LMO4 (Section 1.1.1). Thus, 
amphipathic helices, which have hydrophobic and polar residues segregated on opposite 
sides (88-90), were selected for consideration as they would provide a hydrophobic binding 
face but have properties that promote solubility.  
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Table 5.1: Candidate template α-helices. Bold residues where present represent the key 
binding region to its natural binding partner while the red residues are the key binding 
residues (when known). 
Source Protein 
Name 
Sequence Ref 
Bim1 DMRPEIWIAQELRRIGDEFNAYYARRVFL (61, 91) 
Noxa1 PAELEVECATQLRRFGDKLNFRQKLLNLI (61) 
Puma1 EEQWAREIGAQLRRIADDLNAQYERRRQE (61, 92) 
Bad1 NLWAAQRYGRELRRMSDEFVDSFKKGLPR (61, 93) 
Bik/NBK1 CMEGSDALALRLACIGDEMDVSLRAPRLA (61) 
Bid1 QEDIIRNIARHLAQVGDSMDRSIPPGLVN (61) 
HRK/DP51  RSSAAQLTAARLKALGDELHQRTMWRRRA (61, 94) 
Beclin1 DGGTMENLSRRLKVTGDLFDIMSGQTDVD (61, 95) 
BMF1  QHQAEVQIARKLQCIADQFHRLHVQQHQQ (61) 
VEGF EVVKFMDVYQRSY (35, 96) 
Vammin VRPFLEVHERSA (35, 96) 
p53 SQETFSDWKLLPEN (76, 96) 
Avian Pancreatic 
Polypeptide 
VEDLIRFYDNLQQYLNVV (58, 97) 
HIV-1 Envelope 
protein GP41 
MEWDREINNYTSLIHSCIEESQNQQEKNEQELL (77, 98) 
SOS- αH FFGIYLTNILKTEEG (74, 99) 
1Bim, Noxa, Puma, Bad, Bik/NBK, BID, HRK/DP5, Beclin and BMF are BH3 α-helices.  
It was decided to test three helices from this set in the first instance. The set (Table 5.1) was 
more closely examined for length and amino acid composition to select the peptides that 
would be best-suited to binding to LMO4.  
In terms of length, it was considered desirable to span the whole peptide-binding surface of 
LMO4LIM1 and to allow some flexibility in binding. It was estimated that this would correspond 
to 5-6 turns of helix, so the lower limit in length was set at 24 residues. This excludes VEGF, 
Vammin, p53, Avian Pancreatic Polypeptide and SOS-αH from Table 5.1.  
In terms of amino acid composition, it was decided to exclude those with cysteine residues. 
Cysteines form disulphide bonds, which can be a problem when expressing proteins if 
disulphide bonds form incorrectly and cause misfolding. This criterion excludes Noxa, Bik/NBK 
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and BMF. As discussed in Chapter 4 (Section 4.3) the final residues of LBD1 318 appear to 
adopt a helix-like conformation that could enhance helical formation. Those residues are Glu-
Asp-Glu. It was thought reasonable to look for naturally occurring helices that contain Glu, or 
a similar residue, towards the beginning of the binding region to promote helical formation. 
Candidate helices Bim, Puma, Bad, HRK/DP5, Beclin, GP41 all fit this criterion. To further 
narrow down the selection, simple modelling was carried out to gauge how those helices 
might interact with LMO4LIM1.  
As it is difficult to estimate levels of plasticity of LMO4 and account for changes in 
conformation to accommodate peptide binding, a very simple approach was used to model 
potential interactions. The structures of the helices were manually overlaid on the structure 
of LMO4 bound to LDB1 in PyMOL. General features such as hydrophobicity and potential to 
make electrostatic interactions (and not make unfavourable interactions) were assessed. To 
create the overlays with a reasonable register, a Glu, Gln, Asp or Asn in the helix was aligned 
with Glu318 in LDB1. The rest of the helix was placed along the hydrophobic grove of 
LMO4LIM1.  
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Figure 5.2 LMO4LIM1 and candidate α-helix. The α-helix from (A) Bim, (B) Puma, (C) Bad, (D) 
Beclin, (E) GP41 and (F) Beclin was overlayed onto LMO4LIM1. LMO4 is shown in surface 
representation with YRB colouring: blue is negative, red is positive and yellow is hydrophobic. 
LDB1 (316-318) is shown in green sticks. The hydrophobic binding pocket, where LDB1-Ile321 
binds, is in purple. The α-helices are shown sticks and cartoon, the hydrophobic residues are 
in pale yellow, positively charged residues red, negatively charged residues in blue and polar 
but uncharged residues in grey. The images were generated in PyMOL using PDB files 1RUT 
(21), 1PQ1 (91), 2VOF (92), 1G5J (93), 2PON (95), 1IEX (98) and 2L58 (94).  
 
From the PyMOL overlays (Figure 5.2) the residues in contact with the hydrophobic binding 
groove of LMO4 were assessed residues around the hydrophobic binding pocket (labelled 
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residues). Using this method of alignment, it can be seen that the hydrophobic face of BIM α-
helix fits along the LMO4LIM1 hydrophobic groove (Figure 5.2A). Only hydrophobic and non-
charged residues look to be in contact with LMO4. Leu93 occupies a position similar to that 
of the key binding residue in LDB1, Ile321. Bim BH3 α-Helix was considered a reasonable 
candidate.  
The hydrophobic face of the PUMA α-helix fits along the LMO4LIM1 hydrophobic groove in a 
similar fashion (Figure 5.2B). In this case, Ile144 fits in the hydrophobic binding pocket of 
LMO4LIM1, there were no potential problems indicated by the overlay. PUMA was considered 
a very strong candidate template helix.  
The hydrophobic face of BAD α-helix fits along the LMO4LIM1 hydrophobic groove in a similar 
fashion, but with one notable exception (Figure 5.2C). The residue in contact with the 
hydrophobic binding pocket is Arg312, which carries a positive charge. However, as the long 
sidechain of Arg has a hydrophobic component, it can engage in hydrophobic interactions, 
provided the positively charged end is surface exposed or complemented with a negative 
charge. Note that Arg323, in the key LMO4-binding region of LDB1, appears to make extensive 
hydrophobic interactions with LMO4. In addition, residue Leu311 in BAD, which lies next to 
Arg312 in the sequence could occupy the hydrophobic binding pocket on LMO4. There is 
precedent for rearrangements at this site as CtIPLID uses two residues to bind this site rather 
than one (Chapter 1.1.1). BAD remained a candidate.  
The Beclin α-helix fits along the LMO4LIM1 hydrophobic groove with hydrophobic and 
hydrophilic residues along the LMO4 interface (Figure 5.2D). Lys32 lies in the hydrophobic 
binding pocket of LMO4LIM1. The other residue that is close the pocket is Arg29 (a turn before 
Lys32).  If only one of these residues was positively charged residue, it could probably have 
been incorporated as explained above for Arg312 in BAD. However, the presence of two 
positively charged residues in close proximity to the hydrophobic binding pocket is likely too 
much positive charge to accommodate binding. This rules Beclin out as a test α-helix.  
The GP41 α-helix fits along the LMO4LIM1 hydrophobic groove with hydrophobic and non-
charged residues along the LMO4 interface (Figure 5.2E). Asn50 lies in the hydrophobic 
binding pocket of LMO4LIM1. Although there is a polar amino acid nearby, residues are 
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hydrophobic and small rearrangements could accommodate binding, so GP41 remains a 
candidate.  
Using the standard alignment, the HRK/DP5 α-helix would contact LMO4LIM1 with the 
hydrophilic polar/charged side facing LMO4 and the hydrophobic side on the surface (Figure 
5.2F) which is not desirable. Although other registers might promote binding of the 
hydrophobic surface, the other registers would not work as well with the helical residues 316-
18 of LDB1. HRK/DO5 was eliminated from consideration.  
At this stage there were four candidate peptides BIM, PUMA, BAD and GP41. This set of 
proteins is dominated by BH3-only helices (BIM, PUMA and BAD). It was considered desirable 
to test varied of α-helices, and as GP41 is the only non-BH3 candidate remaining it was 
selected. Of the three BH3 α-helicies PUMA and BIM are very similar to one another, they 
have 38% sequence identity and 55% sequence similarity. BAD only has 21% sequence 
identity with PUMA and 34% similarity, BIM and BAD have 24% sequence identity and 41% 
similarity. As PUMA and BAD are the most different BH3s, PUMA and BAD were chosen. The 
three candidates selected to test in the split EGFP system were GP41, PUMA and BAD  
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5.1 Testing BAD, GP41 and PUMA in the split EGFP system 
 
Figure 5.3 Schematic representations of BAD, GP-41 and PUMA in the split EGFP 
complementation system. The N-terminal fragment (EGFP-A) is tethered to LMO4, and the 
EGFP C-terminal fragment (EGFP-B) is tethered to (A) LDB1 295-318 and BAD; termed BAD; 
(B) LDB1 295-318 and GP41; termed GP41; (C) LDB1 295-318 and PUMA; termed PUMA. (D) 
Pre-existing construct LDB1 318. 
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Figure 5.4 Whole cell fluorescence at 507 nm of E. coli cells expressing the new constructs. 
BL-21 (DE3) cells at grown at 20 °C for 18 h overexpressing constructs as labelled. Cells were 
fixed in PBS with 4% paraformaldehyde. Relative fluorescence of constructs as labelled 
compared to Positive 36 (N = 3 with three technical replicates in each experiment). Samples 
were normalised to a cell density of 0.3 at 0D600nm.  
A 
B 
C 
D 
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The three test α-helices BAD, PUMA and GP41 were cloned into the LDB1 318 construct, 
replacing residues 319 and onwards in LDB1 with the α-helix sequence (Figure 5.3). The new 
constructs were tested for levels of fluorescence by plate fluorimetry and flow cytometry, and 
compared to a range of controls and previously analysed fluorescence constructs. The three 
new constructs BAD, GP41 and PUMA all displayed much higher levels of fluorescence than 
LDB1 318 when analysed in bulk solution (Figure 5.4). The levels were similar to that of LDB1 
315. BAD and GP41 showed levels of relative fluorescence just below that of Positive 36 (81 
± 6 % and 88 ± 3 %, respectively) whereas PUMA displayed a level of fluorescence (105 ± 4 %) 
close to that of Positive 36.  
 
 
Figure 5.5: Flow cytometry EGFP fluorescence of E. coli cells expressing the new constructs. 
For each sample 5 x 104 cells were counted. Fluorescence of EGFP was measured by excitation 
at 480-90 nm and emission at 500-10 nm. Images were generated and overlayed using FlowJo. 
The constructs shown are Positive 36 (green line), Negative 36 (red), LDB1 318 (yellow), LDB1 
315 (orange), BAD (pink), GP41 (Cyan), PUMA (dark blue), Positive 36 EGFP peak (dark green) 
(A) Positive 36, Negative 36, LDB1 318, LDB1 315, BAD, GP41 and PUMA. (B) BAD, GP41, PUMA 
and Positive 36 peak.  
 
One of the replicates for each construct in Figure 5.4 was analysed by flow cytometry to 
provide some preliminary data about the populations of cells. Only fluorescent cells were 
A B 
= Negative 36 = LDB1 318 = Positive 36 = LDB1 315 = GP41 
= BAD = PUMA = Positive 36 Peak Fluorescence 
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used to make the histograms in Figure 5.4; excluding the ~10% non-fluorescent cells from 
each sample. The results for Positive 36, LDB1 315, LDB1 318 and Negative 36 in Figure 5.5A 
were consistent with the previous flow cytometry results (Figure 4.10) and the plate 
fluorimetry data (Figure 5.4). Negative 36 showed a population of cells with low levels of 
expression, and Positive 36 showed a single population of highly fluorescent cells (Figure 
5.5A). LDB1 315 was slightly less fluorescent than Positive 36 and LDB1 318 was less 
fluorescent than Positive 36 and LDB1 315, and more fluorescent than Negative 36. Unlike 
the plate fluorimetry data (Figure 5.4), the new constructs showed peak fluorescence 
populations that were similar to each other and all a bit lower than that for Positive 36 (Figure 
5.4). GP41 had a more significant shoulder in this histogram than the other constructs, 
representing more populations of cells with lower levels of fluorescence. This comparison 
illustrates the depth of information provided by flow cytometry as it registers every cell 
whereas the plate reader provides average values.  
5.3 Optimising Chemical Transformation 
Any library will comprise a set of plasmids with varied sequences at the target positions that 
must be transform BL-21 (DE3) cells. Depending on the number of different sequences in the 
library, this must be a very efficient transformation step to ensure screening of the complete 
library. The standard protocol for bacterial transformation in the laboratory is a chemical 
transformation protocol using thawed aliquots of flash-frozen competent cells. This method 
was selected for its high efficiency in the laboratory compared to other methods for chemical 
transformation that vary slightly (100). However, it is well suited for transforming individual 
plasmids, but is not sufficiently effective for transforming a library. The aim of this section 
was to optimise the transformation procedure for the cells and types of plasmids being used 
(101).  
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Figure 5.6: Representative original transformation plate. LDB1 315 DNA (200 ng) was added 
to 20 μl of chemically supercompetent BL-21 (DE3) cells, incubated on ice for 5 min, heat 
shocked for 90 s at 42 °C, left on ice for 30 s, recovered in LB media for 1 h and plated onto 
LB agar.  
 
Figure 5.6 shows the typical outcome of the standard chemical transformation protocol 
approximately 50 colonies representing the same number of successfully transformed cells 
with approximately 3 x 1010 plasmids in 200 ng DNA. To transform a library a much more 
efficient method is required. To optimise the protocol I varied three different parameters in 
the standard method (Figure 5.7) and four different recovery media (Figure 5.8). In each case 
cells were made super-competent by using freshly cultured BL-21 (DE3) cells according to 
Section 2.4.2, without the freezing, storage and thawing that is part of the standard protocol. 
Over 100 transformations were performed varying the time parameters according to Table 
5.7 and the recovery media according to Table 5.8, each unique combination was repeated 
three times, where each replicate used each a different plasmid (Positive 36, LDB1 318 and 
Negative 36). The full data from these experiments is provided in Appendix A).  In this section 
representative plates are shown.  
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Table 5.7: Times for each of the components in the heat shock protocol.  
Method Resting Ice Time (min) Heat Shock Time (s) Ice time (min) Recovery Time (h) 
1 5-10 90 0.5 1 
2 30 90 30 1.5-2 
3 30 60 2 1-1.5 
Method 1 is the standard protocol.  
These three methods represent three common sets of parameters used in the 
Mackay/Matthews lab. Method 1 (the standard protocol) is from Dr Philippa Stokes, Method 
2 from Dr Neil Robertson and Method 3 from Dr Jason Low.  
Table 5.8: Recovery Media and Components. 
Recovery 
Media 
Components 
LB 1% w/v Tryptone, 0.5% w/v Yeast Extract, 0.17 M NaCl 
SOB 2% w/v Tryptone, 0.5% w/v Yeast Extract, 10 mM NaCl, 2.5 mM KCl, 10 mM 
MgCl2, 10 mM MgSO4 
SOC 2% w/v Tryptone, 0.5% w/v Yeast Extract, 10 mM NaCl, 2.5 mM KCl, 10 mM 
MgCl2, 10 mM MgSO4, 20 mM Glucose 
YT 2% w/v Tryptone, 0.5% w/v Yeast Extract, 0.1 M NaCl 
LB is the current recovery media 
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5.3.1 Results of Transformation Optimisation Experiments  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9: Representative transformation plate for Method 1. LDB1 318 DNA (100 ng) was 
added to 20 μl of chemically supercompetent BL-21 (DE3) cells, incubated on ice for 10 min, 
heat shocked for 90 s at 42 °C, left on ice for 30 s, recovered for 1 h in (A) LB media (B) SOC 
media (C) SOB media and (D) YT media. Cells were plated onto LB agar.  
 
Varying the recovery media for the original method revealed an approximate three-fold 
increase in colony number with YT media (150 colonies) (Figure 5.9). SOC, SOB and LB 
recovery media all have approximately 50 colonies.  
 
 
A B 
D C 
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Figure 5.10: Representative transformation plates for Method 2. LDB1 318 DNA (100 ng) was 
added to 20 μl of chemically supercompetent BL-21 (DE3) cells, incubated on ice for 30 min, 
heat shocked for 90 s at 42 °C, left on ice for 30 min, recovered for 1.5 h in (A) LB media (B) 
SOC media (C) SOB media and (D) YT media. Cells were plated onto LB agar.  
 
For Method 2, YT media again gave the highest number of colonies, ~50 (Figure 5.7). LB, SOC 
and SOB resulted in less than 10 colonies per transformation. All the plates here have fewer 
colonies than the corresponding plates in Figure 5.9, suggesting that Method 2 is not an 
improvement on the original method.  
 
 
A B 
C D 
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Figure 5.11: Representative transformation pate for Method 3. LDB1 318 DNA (100 ng) was 
added to 20 μl of chemically supercompetent BL-21 (DE3) cells, incubated on ice for 30 min, 
heat shocked for 60 s at 42 °C, left on ice for 2 min, recovered for 1 h in (A) LB media (B) SOC 
media (C) SOB media and (D) YT media. Cells were plated onto LB agar.  
 
Method 3 resulted in approximately 50 colonies for LB, SOC and SOB and 1000 colonies for 
YT (Figure 5.11). For Methods 1 and 3 recovery in YT media resulted in the largest number of 
colonies, which was substantially higher for Method 3.  
A B 
C D 
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Figure 5.12: YT transformation plates. Supercompetent BL-21 (DE3) cells, incubated on ice 
for 30 min, heat shocked for 60 s at 42 °C, left on ice for 2 min, recovered for 1 h in (A) LDB1 
318 DNA (300 ng) was added to 30 μl cells (B) LDB1 318 DNA (50 ng) was added to 20 μl cells.  
 
Further attempts were made to increase the transformational efficiency of Method 3 with YT 
media by increasing the volume of cells being transformed and varying the DNA (ng)-to-cells 
(μl) ratio. Increasing the cell volume or this ratio did not increase the colony number (Figure 
5.12 and Appendix A). For example, 300 ng DNA in 30 μl cells yielded ~1000 colonies (Figure 
5.12A). In contrast, decreasing the amount of DNA to 50 ng decreased the colony number by 
approximately half (Figure 5.12B), and smaller amounts of DNA further decreased the colony 
number (Appendix A).  
Overall, these experiments indicate that Method 3, with recovery in YT media using 100 ng 
DNA and 20 μl cells is optimal for these cells. This corresponds to ~1000 colonies from 1.4 x 
1010 plasmids from a single transformation experiment, or ~104 cfu (colony forming units)/µg 
DNA 
5.5 Plasmid Extraction Optimisation  
The sequence of the LMO4-peptides will be identified by DNA-sequencing of plasmids 
extracted from highly fluorescing cells isolated by FACS. The cells used for expression of the 
split EGFP system, BL-21(DE3), belong to a strain that was optimised for protein expression 
rather than plasmid transformation, amplification and DNA extraction. A variant strain, BL-
21(DE3) Gold, possesses an inactivated endonuclease I gene, endA, that can degrade plasmid 
DNA isolated by most miniprep procedures (102).  
A B 
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I sought to compare plasmid extracted from BL-21 (DE3) and BL-21 (DE3) Gold cells and 
compared these to our standard cell line for plasmid amplification and extraction, DH5α cells. 
I also compared two commercially available miniprep kit used to extract the DNA in use in our 
Laboratory, from Bioline and from Qiagen. Cells were transformed with Positive 36 and 
Negative 36 plasmids, minipreps carried out according to the Manufacturers’ instructions 
(including all optional wash steps) and the resultant preparations analysed by agarose gel 
electrophoresis (Figure 5.13). 
 
 
 
 
 
Figure 5.13. Comparison of plasmid extraction efficacies for mini-prep kits. 500 ng of plasmid 
(as estimated by spectrophotometry) were run on 1% Agarose gels at 110 v, 400 mA for 40 
min and visualised with hydra green.  
A correctly sized band on an Agarose gel is a good indication of the presence and quality of 
the plasmid. For the plasmids prepared using the Bioline kit there were no DNA bands visible 
except for a very faint one for Negative 36 (Figure 5.13B, lane 4). For plasmids prepared using 
the Qiagen kit bands of the correct size (6.5 kb) were observed. These data indicate that the 
Qiagen kit is more appropriate for extracting plasmid DNA from cells. The cell type used did 
not appear to influence if a DNA band was observed. The yields of the plasmids as estimated 
by spectrophotometry, along with measures of purity as estimated by the ratios of 
absorbance at 260/280 (to check for protein contamination) and 230/260 (to check for 
1. Ladder 
2. DH5α Bioline 
3. BL-21 (DE3) Bioline 
4. BL-21 (DE3) Gold Bioline 
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carbohydrate contamination), appearance of bands (Figure 5.13) and success in DNA 
sequencing (Section 2.2) are reported in Tables 5.14/15.  
Table 5.14: Plasmid yields for Positive 36. 
Construct Positive 36 
Cell Type  DH5α BL-21 (DE3) BL-21 (DE3) Gold 
Plasmid 
Extraction 
Kit  
Bioline Qiagen Bioline Qiagen Bioline Qiagen 
Avg Yield 
(ng) 
98 90 95 127 47 94 
Avg 
A260/280 
1.8 2.1 1.8 1.9 1.9 1.9 
Avg 
A230/260 
1.1 2.3 1.3 2.3 1.0 2.3 
Gel Band no yes no yes No yes 
Sequencing 
Success 
no yes no yes No yes 
Preparations were carried out in triplicate (biological replicates) apart from DNA sequencing 
(one sample only). 
Table 5.15: Plasmid yields for Negative 36. 
Construct Negative 36 
Cell Type  DH5α BL-21 (DE3) BL-21 (DE3) Gold 
Plasmid 
Extraction 
Kit  
Bioline Qiagen Bioline Qiagen Bioline Qiagen 
Avg Yield 
(ng) 
86 89 105 131 78 130 
Avg 
A260/280 
1.8 2.0 1.8 1.8 1.8 1.9 
Avg 
A230/260 
0.9 2.3 1.0 2.3 1.2 2.2 
Gel Band no yes no yes yes yes 
Sequencing 
Success 
no yes no yes no yes 
Preparations were carried out in triplicate (biological replicates) apart from DNA sequencing 
(one sample only) 
 
The yields estimated by spectrophotometry (absorbance at 260 nm) were generally higher for 
the Qiagen rather than the Bioline preparations, although there was some variation (Tables 
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5.14/15). Pure DNA preparations are expected to have an A260/280 ratio of ~1.8, with lower 
values indicating contamination with protein (103). None of the reported values suggest this 
problem. The A230/260 ratio has an expected range of 2.0-2 for pure samples with lower 
values being a marker of carbohydrate and/or phenol contamination (103). The values for the 
Qiagen kit preparations fall inside or just outside this range, but those for the Bioline 
preparation were much lower. Carbohydrate and/or phenol contamination may be the reason 
DNA bands were not seen in agarose gels and sequencing is of poor quality.A Qiagen kit will be 
used to extract the library plasmids out of the sorted cells. The data does not show the BL-21(DE3) 
Gold strain having any improvements in DNA extraction over the standard BL-21(DE3) strain. 
5.6 Conclusion and Future Directions  
In this Chapter naturally occurring α-helices were identified from the literature and examined 
for their use as templates in the split EGFP selection screen on the basis of length, amino acid 
composition and potential to form interactions with LMO4. BAD, GP41 and PUMA were 
selected to be tested and cloned into the split EGFP vectors, which were expressed in cells 
and fluorescence measured by plate fluorimetry and flow cytometry. There were some 
differences observed between the fluorescence data obtained by these methods. The plate 
fluorimetry indicated that the GP41, BAD constructs had levels of fluorescence that were just 
below that of the positive control, whereas that of PUMA was equivalent to that in Positive 
36 (Figure 5.3). However, the flow cytometry data indicated that all three helical constructs 
resulted in levels of fluorescence that were close to that of LDB1 315, but less than Positive 
36 (Figure 5.4). Note that only one set of flow cytometer experiments was completed, so it 
should be repeated for reliability. However, it is clear from these studies that plate fluorimetry 
reports average values for the whole cell population, which can be misleading, especially if 
there are varied numbers of non-fluorescing cells, whereas flow cytometry reports data for 
each individual cell and provides information about different populations of cells. 
As discussed for LDB1 315 (Chapter 4.4), the data for BAD, GP41 and PUMA could indicate 
that those helices bind non-specifically to LMO4. Indeed, they were selected as having a 
hydrophobic face that had the potential to interact with LMO4 (Chapter 1). It is not possible 
to tell from these data if the interactions are specific or not.  Rather it will be necessary to 
express and purify the BAD, GP41 and PUMA constructs for structural characterisation. This 
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would include circular dichroism studies to look for differences in helicity compared with 
LMO4-LID complexes, as well as size exclusion chromatography and light scattering to assess 
oligomeric state, and NMR and/or X-ray crystallography studies to determine if the helices do 
bind as intended or exhibit non-specific binding.  
Regardless, these high values for BAD, GP41 and PUMA mean that there will be a high baseline 
from which increases in fluorescence would be measured, which may not provide sufficient 
dynamic range from improved binding. Alternate options include exploration of different 
mutations in the LDB1 LMO4LIM2 binding region to weaken that interaction and thus lower the 
overall baseline fluorescence. It may be possible to dispense with the LMO4LIM2 and 
corresponding region of LDB1 (295-318) altogether.  
The protocols of chemical transformation and DNA extraction were optimised for maximal 
efficiency for potential screening. The improved protocol for transformation is to incubate 
100 ng of plasmid DNA in 20 μl of super competent BL-21 (DE3) cells on ice for 30 min followed 
by heat shock at 42 °C for 1 min, resting on ice for 2 min and recovery in YT media for 1 h. This 
method resulted in 1000 colonies on a standard 10-cm agar plate, which is a greater than 20-
fold improvement over the original protocol. Much of the improvement in chemical 
transformation efficiency was due to changing the recovery media to YT (Figures 5.10-15). 
Further experiments would need to be conducted to know which media components (Table 
3) are responsible, but perhaps YT sits in the sweet spot for these cells, being a very rich media 
with high levels of Tryptone and enough salt to help the bacteria grow (more than SOB/SOC) 
but not so much that it impacts growth (less than LB). However, despite the improvements, 
the efficiency of transformation may still be insufficient for library transformations. 
Electroporation, which utilises and electric current to permeabilise cells, and/or the use of 
commercially prepared component cells should be investigated to further increase 
transformation efficiency. 
For DNA extraction, it was not necessary to switch from our BL-21 (DE3) cells to another cell 
line that is optimised for plasmid recovery. This result was surprising, as BL-21(DE3) cells are 
usually considered to be poor candidates for plasmid extraction. It is possible that our strain 
has changed over time, but it would also be worth confirming if we are using BL-21(DE3) cells, 
or if they are mislabelled BL-21(DE3)Gold cells. This could be checked by testing for 
tetracycline resistance as BL-21(DE3) Gold cells are resistant to this antibiotic whereas BL-
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21(DE3) cells are not. Regardless, when those cells were used in combination with the Qiagen 
mini-prep kit sufficient high quality DNA was produced for DNA-sequencing (Table 4 and 5).  
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Future Directions  
Specific inhibitors of LMO4 that allow LMO4 activity to be modulated would provide tools 
with which to probe the functions of LMO4 and LMO4-interacting proteins. Understanding 
the function of LMO4 in different cells types will allow greater understanding of LMO4 in 
human biology, particularly in terms of development and the onset and/or progression of 
breast cancer. Inhibitory peptides themselves are unlikely to be useful therapeutics, but they 
could be used to establish proof of principle that inhibiting LMO4 is a useful strategy for 
therapy. The peptides would, however, be useful reagents to aid the development of small 
molecule drug inhibitors that could be used to treat breast cancer. In particular α-helical 
peptides could be converted into α-helical mimetics - compounds that use non-natural 
chemistry to stabilise the helical structure that are highly resistant to proteolysis. α-Helical 
mimetics are showing good promise as drug candidates (63, 73, 104). The approach outlined 
in this thesis for finding specific α-helical inhibitors of β-strand peptide binding domain may 
be useful for finding inhibitors for other β-peptide binding proteins that would have broad 
uses in medical research, biotechnology and agriculture.  
The aim of this thesis was to develop methods to identify α-helical peptides from a library of 
α-helical peptides that bind to LMO4. The split EGFP complementation system was further 
developed to target LMO4LIM1 through the incorporation of the LDB1 318 construct. This 
construct was subsequently tested with three naturally occurring template α-helices. The 
fluorescence results for results for PUMA, BAD and GP41 by flow cytometry and plate 
fluorimetry reveal a background fluorescence that is too high for FACS to identify tighter 
binding peptides. It may be that these helices are binding to LMO4 as intended, which needs 
to be assessed by structural and biophysical characterisation as outlined in the previous 
chapter (Section 5.2). 
Regardless, for the split EGFP system to work we need to reduce the background fluorescence 
as discussed in the previous Chapter (Section 5.2), perhaps by introducing destabilising 
mutations or dispensing with the LMO4LIM2 binding components. The next stage is to design 
an initial test library. In library design we want to focus on small smart libraries to maximise 
the chance of finding peptides with increased affinity to LMO4.  
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Traditional large libraries use either use a naive completely randomised sequence or a 
template peptide and then perform saturation mutagenesis to create extremely large 
libraries of peptides. Saturation mutagenesis libraries have a very low probability of finding 
peptides that bind better to the target, as approximately 30% of the library is significantly 
worse at binding the target (105). Given this low efficiency it makes sense to use a small smart 
libraries (106). A small smart library uses structural information to identify which residues are 
most likely to be involved in binding and to specifically mutate these residues to amino acids 
that could improve binding (107). Small changes and substitutions of one amino acid for 
another can have great effects, both positive and negative, on binding affinity (108). Although 
we don’t yet have structures of the template helices bound to LMO4, we can use information 
from the structures of LMO4 in complex with LDB1, CtIP-1 and Deaf-1 to provide information 
about what kind of residues would be useful in which locations. In particular, we can target 
the hydrophobic binding pocket of LMO4LIM1 by making libraries biased towards hydrophobic 
residues in likely binding positions. We have already identified the hydrophobic faces of the 
amphipathic helices as the likely LMO4-interaction surfaces (Figure 5.2) and intend to select 
a small number of sites for targeted mutagenesis. For example, the sequence of PUMA is 
EIGAQLRRIADDLNAQYERRRQE where bold indicates residues in the main binding region for 
its natural target BCL-XL and red indicates residues directly involved in binding. From Figure 
5.2 we predict that the Ile114 (blue) will bind in the hydrophobic binding pocket 
(EIGAQLRRIADDLNAQYERRRQE). We would initially select residues for mutation that are 
predicted to lie in or around this pocket. Because of the 3-dimensional structure of helices, 
these will be separated in sequence and are indicated in pink, EIGAQLRRIADDLNAQYERRRQE.  
Whereas full randomisation of sites could use NNN codons (equimolar amounts of A, C, G and 
T at each position), it is more common to use restricted codons (NNS or NNK where S is G or 
C, and K is G or T) to reduce library size and even out representation of amino acids. While all 
three schemes encode every amino acid, they also include stop codons that will cause a 
fraction of peptides to be truncated. However, other selective codon schemes (Figure 5.10) 
encode subsets of the amino acids (109) and can avoid stop codons altogether.  
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Table 1: Partially degenerate codon schemes. 
Codon  Description  Amino Acids  Stop codons  
NTN  Hydrophobic M,F,L,I,V None  
NTT Hydrophobic F, I L, V  None  
RVK Charged Hydrophobic  D, E, F, H, I, K, N, R, S, T  TAA 
TDK Hydrophobic C, F, L, W, Y TAG 
NNT Mixed  A, D, G, H, I, L, N, P, R, S, T, V None  
NNC 15 aa A, D, F, G, H, I, L, N, P, R, S, T, V, Y, None 
NDT 12aa C, D, F, G, H, I, L, N, R, S,V,Y  None  
NAN Charged larger side chains  D,E,H,K,N,Q,Y TAA, TAG 
NCN Smaller side chains  A, P,S,T None 
RST Small side chains  A,G,S,T None 
VVC Hydrophilic A,D,F,H,N,P,R,S,T None 
DVT Hydrophilic A,C,D,G,N,S,T,Y None 
NNW Charged, hydrophobic D,E,F,H,I,K,L,N,Q,V,Y TAA 
Equimolar mixtures. N - all nucleotides; D - A/G/T; K - G/T; R - A/G; S - G/C; V - A/C/G; W - A/T.  
As we want to focus on hydrophobic residues, we can focus on codon schemes that result in all or 
predominantly hydrophobic residues. We can also eliminate schemes that contain one or more stop 
codons. Four possible schemes NTN, NTT, NNT and NDT could be suitable. NTN and NTT code for five 
and four amino acids, respectively, whereas NNT and NDT encode 15 and 12 amino acids, respectively. 
We prefer a smaller rather than a large initial library so would likely use NTT or NTN. As the latter 
includes an extra hydrophobic amino acid (Met), it is a likely candidate.  
Attempts were made to use mCherry to control for expression levels in the cells. Due to cloning 
difficulties only three constructs with mCherry were tested. In order to properly asses if mCherry can 
be useful as an expression control a complete set of constructs will need to be examined. 
In conclusion, thesis has made significant improvements to the split EGFP complementation system 
and Y2HCA validation systems. The Y2HCA has one additional construct (M3-LMO4) to help 
qualitatively asses the relative binding affinities of weak peptides and another to stabilise LMO4 and 
better visualise weak binders (M2-LMO4). The split EGFP system now has positive and negative 
controls and can incorporate α-helical peptides that have been designed to bind LMO4LIM1. 
Improvements were made to a chemical transformation and a method to extract plasmid DNA from   
BL-21(DE3) cells was established.  
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 Appendix A 
Method  DNA (ng)  Cells (μl) Recovery media  Colonies  
3 100 20 YT 1000 
3 300 30 YT 1000 
3 150 20 YT 1000 
3 50 20 YT 750 
3 250 50 YT 750 
1 250 50 YT 250 
1 300 20 YT 200 
1 150 20 YT 200 
1 250 50 LB 155 
2 250 50 YT 150 
2 300 20 YT 150 
1 100 20 YT 150 
3 250 50 LB 150 
3 250 50 SOC 150 
3 144 20 LB 150 
1 250 50 SOC 150 
3 240 50 SOB 125 
2 150 20 YT 120 
3 200 20 LB 115 
2 100 20 YT 100 
3 300 20 LB 100 
3 200 40 LB 100 
1 200 40 LB 100 
1 300 20 LB 100 
3 250 20 LB 90 
1 250 20 LB 75 
3 250 50 SOB 70 
3 100 20 LB 60 
3 300 60 LB 60 
3 100 20 SOB 60 
1 250 50 SOB 60 
3 150 20 SOB 60 
3 150 30 LB 50 
3 100 20 SOC 50 
3 150 30 SOC 50 
3 200 40 SOC 50 
3 300 60 SOC 50 
1 200 20 LB 50 
1 144 20 LB 50 
1 100 20 SOB 50 
1 100 20 SOC 50 
100 
 
1 100 20 LB 50 
1 150 30 LB 50 
1 300 60 LB 50 
1 150 30 SOC 50 
1 200 40 SOC 50 
1 300 60 SOC 50 
1 150 30 SOB 50 
1 200 40 SOB 50 
1 300 60 SOB 50 
3 100 20 SOB 50 
3 150 30 SOB 50 
3 200 40 SOB 50 
3 300 60 SOB 50 
1 50 20 LB 42 
3 50 20 LB 37 
1 100 20 LB 20 
1 100 20 SOC 14 
1 100 20 SOB 12 
2 100 20 LB 6 
2 100 20 SOC 3 
2 100 20 SOB 3 
3 5 20 LB 1 
3 0.5 20 LB 0 
3 0.05 20 LB 0 
3 0.005 20 LB 0 
 
Full data for chemical transformation optimisation experiments. Methods 1-3 are described 
in Figure 5.11 and Section 2.4.5. Methods 1-3 describe a transformation protocol which 
have a range of possible amounts of DNA, cell volumes and recovery media. The exact DNA 
amount, cell volume and recovery media used in each transformation is indicated in the 
table.  The times and other steps indicated in the Methods were not varied.  Data are 
arranged in descending order of colonies obtained. 
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Appendix  B – Protein Sequences  
Protein sequences of constructs generated in the thesis  
LDB1 318 
 
MGSSHHHHHHSSGLVPRGSHMSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVP
WPTLVTTLTYGVQCFARYPDHMKQHDFFKSAMPEGYVQERTISFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKE
DGNILGHKLEYNYNSHNVYITADKQKGGGGSGGGGSLSWKRCAGCGGKIADRFLLYAMDSYWHSRCLKCSSCQA
QLGDIGTSSYTKSGMILCRNDYIRLFGNSGACSACGQSIPASELVMRAQGNVYHLKCFTCSTCRNRLVPGDRFHYIN
GSLFCEHDRPTALINGHLNSGGSGGLEVLFQGPGGSGGSSQVPDVMVVGEPTLMGGEFGDEDERLITRLENTQFD
AANGIDDEEFGGGGSGGGGSNGIKANFKIRHNIEDGGVQLADHYQQNTPIGDGPVLLPDNHYLSTQSKLSKDPNE
KRDHMVLLEFVTAAGITHGMDELYK 
 
LDB1 318 mutant 
 
MGSSHHHHHHSSGLVPRGSHMSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVP
WPTLVTTLTYGVQCFARYPDHMKQHDFFKSAMPEGYVQERTISFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKE
DGNILGHKLEYNYNSHNVYITADKQKGGGGSGGGGSLSWKRCAGCGGKIADRFLLYAMDSYWHSRCLKCSSCQA
QLGDIGTSSYTKSGMILCRNDYIRLFGNSGACSACGQSIPASELVMRAQGNVYHLKCFTCSTCRNRLVPGDRFHYIN
GSLFCEHDRPTALINGHLNSGGSGGLEVLFQGPGGSGGSSQVPDVMVVGEPTLMGGEFGDEDERLITRLENTQFD
AANGIDDEEFGGGGSGGGGSNGIKANFKIRHNIEDGGVQLADHYQQNTPIGDGPVLLPDNHYLSTQSKLSKDPNE
KRDHMVLLEFVTAAGITHGMDELYK 
 
LDB1 315 
MGSSHHHHHHSSGLVPRGSHMSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVP
WPTLVTTLTYGVQCFARYPDHMKQHDFFKSAMPEGYVQERTISFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKE
DGNILGHKLEYNYNSHNVYITADKQKGGGGSGGGGSLSWKRCAGCGGKIADRFLLYAMDSYWHSRCLKCSSCQA
QLGDIGTSSYTKSGMILCRNDYIRLFGNSGACSACGQSIPASELVMRAQGNVYHLKCFTCSTCRNRLVPGDRFHYIN
GSLFCEHDRPTALINGHLNSGGSGGLEVLFQGPGGSGGSSQVPDVMVVGEPTLMGGEFGDEDERLITRLENTQFE
FGGGGSGGGGSNGIKANFKIRHNIEDGGVQLADHYQQNTPIGDGPVLLPDNHYLSTQSKLSKDPNEKRDHMVLLE
FVTAAGITHGMDELYK 
LDB1 315 mutant 
MGSSHHHHHHSSGLVPRGSHMSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVP
WPTLVTTLTYGVQCFARYPDHMKQHDFFKSAMPEGYVQERTISFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKE
DGNILGHKLEYNYNSHNVYITADKQKGGGGSGGGGSLSWKRCAGCGGKIADRFLLYAMDSYWHSRCLKCSSCQA
QLGDIGTSSYTKSGMILCRNDYIRLFGNSGACSACGQSIPASELVMRAQGNVYHLKCFTCSTCRNRLVPGDRFHYIN
GSLFCEHDRPTALINGHLNSGGSGGLEVLFQGPGGSGGSSQVPDVMVVGEPTLMGGEFGDEDERLITRLENTQFE
FGGGGSGGGGSNGIKANFKIRHNIEDGGVQLADHYQQNTPIGDGPVLLPDNHYLSTQSKLSKDPNEKRDHMVLLE
FVTAAGITHGMDELYK 
mCherry 
MVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAWDILSP
QFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYKVKLRGTNFPSD
GPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYKAKKPVQLPGAYNVNIKL
DITSHNEDYTIVEQYERAEGRHSTGGMDELYK 
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PUMA 
MGSSHHHHHHSSGLVPRGSHMSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVP
WPTLVTTLTYGVQCFARYPDHMKQHDFFKSAMPEGYVQERTISFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKE
DGNILGHKLEYNYNSHNVYITADKQKGGGGSGGGGSLSWKRCAGCGGKIADRFLLYAMDSYWHSRCLKCSSCQA
QLGDIGTSSYTKSGMILCRNDYIRLFGNSGACSACGQSIPASELVMRAQGNVYHLKCFTCSTCRNRLVPGDRFHYIN
GSLFCEHDRPTALINGHLNSGGSGGLEVLFQGPGGGSSTLYCQFPITIVEQSRQCLHNSYAWPRRIFTDVVMCLGK
KGSTWLTEFGGGGSGGGGSNGIKANFKIRHNIEDGGVQLADHYQQNTPIGDGPVLLPDNHYLSTQSKLSKDPNEK
RDHMVLLEFVTAAGITHGMDELYK 
BAD 
MGSSHHHHHHSSGLVPRGSHMSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVP
WPTLVTTLTYGVQCFARYPDHMKQHDFFKSAMPEGYVQERTISFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKE
DGNILGHKLEYNYNSHNVYITADKQKGGGGSGGGGSLSWKRCAGCGGKIADRFLLYAMDSYWHSRCLKCSSCQA
QLGDIGTSSYTKSGMILCRNDYIRLFGNSGACSACGQSIPASELVMRAQGNVYHLKCFTCSTCRNRLVPGDRFHYIN
GSLFCEHDRPTALINGHLNSGGSGGLEVLFQGPGGGSSTLYCQFPITIVEQSRQCLHNSYAWPRRIFTDVVMCLEFG
GGGSGGGGSNGIKANFKIRHNIEDGGVQLADHYQQNTPIGDGPVLLPDNHYLSTQSKLSKDPNEKRDHMVLLEFV
TAAGITHGMDELYK 
GP41 
MGSSHHHHHHSSGLVPRGSHMSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVP
WPTLVTTLTYGVQCFARYPDHMKQHDFFKSAMPEGYVQERTISFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKE
DGNILGHKLEYNYNSHNVYITADKQKGGGGSGGGGSLSWKRCAGCGGKIADRFLLYAMDSYWHSRCLKCSSCQA
QLGDIGTSSYTKSGMILCRNDYIRLFGNSGACSACGQSIPASELVMRAQGNVYHLKCFTCSTCRNRLVPGDRFHYIN
GSLFCEHDRPTALINGHLNSGGSGGLEVLFQGPGGGSSTLYCQEWQTYRIPLMNGHDECVDAWPRRIFTDVVMC
LGKKGSTWLTEFGGGGSGGGGSNGIKANFKIRHNIEDGGVQLADHYQQNTPIGDGPVLLPDNHYLSTQSKLSKDP
NEKRDHMVLLEFVTAAGITHGMDELYK 
M3-LMO4 
GSSLQNNQDVSFENIQWSIDPGADLSQYKAAATVIDTKDGSQSKLGGGGSGGHMGSGGLSWKRCAGCGGKIAD
RFLLYAMDSYWHSRCLKCSCCQAQLGDIGTSCYTKSGMILCRNDYIRLFGNSGACSACGQSIPASELVMRAQGNVY
HLKCFTCSTCRNRLVPGDRFHYINGSLFCEHDRPTALINGHLNS 
M668A-LMO4  
GSSLQNNQDVSFENIQWSIDPGADLSQYKMDVAAADTKDGSQSKLGGGGSGGHMGSGGLSWKRCAGCGGKIA
DRFLLYAMDSYWHSRCLKCSCCQAQLGDIGTSCYTKSGMILCRNDYIRLFGNSGACSACGQSIPASELVMRAQGN
VYHLKCFTCSTCRNRLVPGDRFHYINGSLFCEHDRPTALINGHLNS 
D669A-LMO4 
GSSLQNNQDVSFENIQWSIDPGADLSQYKAAATVIDTKDGSQSKLGGGGSGGLEVLFQGPGGSGGLSWKRCAGC
GGKIADRFLLYAMDSYWHSRCLKCSCCQAQLGDIGTSCYTKSGMILCRNDYIRLFGNSGACSACGQSIPASELVMR
AQGNVYHLKCFTCSTCRNRLVPGDRFHYINGSLFCEHDRPTALINGHLNS 
V670A-LMO4 
GSSLQNNQDVSFENIQWSIDPGADLSQYKMDVAAADTKDGSQSKLGGGGSGGLEVLFQGPGGSGGLSWKRCA
GCGGKIADRFLLYAMDSYWHSRCLKCSCCQAQLGDIGTSCYTKSGMILCRNDYIRLNSGACSACGQSIPASELVMR
AQGNVYHLKCFTCSTCRNRLVPGDRFHYINGSLFCEHDRPTALINGHLNS 
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Appendix C – Primers 
Oligonucleotides used as PCR primers are listed below 
Name Sequence (5’-3’) 
LMO4pgbt9REV 
TCGCCCGGAATTAGCTTGGCTGCAGAATTCTCAGGAGTTCAAAT
GGCC 
M668Afor CTTTCTCAGTATAAAGCGGATGTTACTGTAATA 
M668Arev TATTACAGTAACATCCGCTTTATACTGAGAAAG 
D669Afor CTCAGTATAAAATGGCTGTTACTGTAATAGA 
D669Arev TCTATTACAGTAACAGCCATTTTATACTGAG 
V670Afor AGTATAAAATGGATGCTACTGTAATAGATAC 
V670Arev GTATCTATTACAGTAGCATCCATTTTATACT 
LMO4 153 GEX R CGTCTAGCAGTCAGTCAGTCGCTACTTAAG 
GEX CtIP641 F CCAAAATCGGATCTGGTTCCGCGTGGATCCTCTCTACAAAACAAC
CAAG 
pET15gibson_For 
AGCGGCCTGGTGCCGCGCGGCAGCCATATGTCTAAGGGCGAAG
AACTGTTT 
pET15gibson_Rev 
TCCTTTCGGGCTTTGTTAGCAGCCGTCGACTCATTACTTGTACAGC
TCATCCATAC 
LMO4GFPForGib GGTGGCGGCGGTTCTGGCGGTGGTGGATCCCTCTCCTGGAAGCG 
330LDB1GFPRevGib 
GCCACCACCGGAACCACCGCCACCGAATTCAAACTGGGTGTTCTC
C 
 36nonsenseGFP  
GCCACCACCGGAACCACCGCCACCGAATTCAAGGCACATTACAA
CAT 
LDB1(295-
318)Nonsense Rev CCATGTTACAATGGCCATTCC 
Duet1EGFPfor AGCAGCCATCACCATCATCACCACAGCCAGGGCCTGGTGCCG 
Duet1EGFPrev 
AAGCTTGTCGACCTGCAGGCGCGCCGAGCTTCATTACTTGTACAG
CTC 
Duet2mchefor ATTAGTTAAGTATAAGAAGGAGATATACATATGGTGAGCAAGGG 
Duetmchery2rev 
AAATTTCGCAGCAGCGGTTTCTTTACCAGACTTGTACAGCTCGTC
C 
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Appendix D – SD Media 
Media Additional Components 
SD-LW 200 mg/L adenine, 200 mg/L histidine 
SD-LWH 200 mg/L adenine 
SD-LWHA None  
X-α-gal 40 μg/mL where used 
 
